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Abstract 
 
Autophagy is a critical survival mechanism facilitating protein turnover and 
pathogen defense in post-mitotic cells.  More recently, mitophagy has been identified for 
the selective recognition and targeting of mitochondria for degradation.  Mitochondrial 
availability is the net result of organelle catabolism via mitophagy and mitochondrial 
biogenesis.  Although the latter process has been well described, mitophagy in skeletal 
muscle is less understood, and it is unknown how these two opposing mechanisms 
converge during contractile activity.  We employed an in vitro model of chronic 
contractile activity (CCA) of myotubes in cell culture in the presence of autophagy 
inhibitor Bafilomycin A1 (BafA) and assessed the implications of defective autophagy on 
the adaptations to contractile activity.  BafA lead to severe deficits to mitochondrial 
respiration and enhanced reactive oxygen species.  CCA ameliorated this defective 
phenotype, reverting levels back towards untreated controls.  Thus, contractile activity 
normalizes mitophagy flux and maintains a healthier mitochondrial profile during 
autophagy deregulation.   
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1.0 Mitochondria 
The evolutionary success of eukaryotes is attributed to the advent of aerobic 
respiration.  The atmospheric availability of oxygen permitted the selection and adaptive 
success of organisms that utilized a strong oxidizing agent in the generation of chemical 
energy.  Nearly all eukaryotes rely on mitochondria for the majority of their energy 
production, and thus survival.  Mitochondria are dynamic, ovoid or reticular intracellular 
structures, comprised of outer and inner phospholipid bi-layers.  Easily identified in 
electron micrographs, their characteristic inner membrane convolutions termed cristae 
run in a parallel formation, and function to significantly enhance the surface area of their 
constituent membranes.  Early qualitative observations suggested that the complexity and 
abundance of cristae was correlated to the aerobic capacity of the tissue.  Highly 
oxidative tissues such as heart, kidney and brain, are populated by mitochondria with a 
greater cristae density (37).  The inner membrane houses enzyme complexes, collectively 
termed the electron transport chain (ETC), that allow for the generation of ATP, the core 
energy currency of the cell.   Residing between the cristae is the inner-membrane space 
coined the matrix.  Mitochondrial morphology is dictated by both physiological and 
pathological conditions, and their  reticular formation was found to defend the organelle 
from degradation (144).  In addition, it allows for a more efficient diffusion of 
metabolites and substrates, and is intricately coupled to the bioenergetics of the organelle 
(8).  A distinctive feature of the mitochondrion is an inherent genome, resembling the 
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circular DNA of prokaryotes.  The organelle is an assembly of proteins encoded by both 
nuclear DNA and mitochondrial DNA (mtDNA).  The mitochondrial genome contains a 
total of 37 genes, encoding proteins of 2 ribosomal subunits, 22 transfer RNAs and 13 
mitochondrial proteins.  These complex organelles are made up of in excess of a 
thousand total proteins, the majority of which are nuclear-encoded, and rely on import for 
their concerted integration.  Mitochondrial transcription factor A (TFAM) regulates the 
transcription of mtDNA, while peroxisome proliferator-activated receptor gamma co-
activator (PGC-1α) allows for the coordinated expression of both genomes.   
1.1 Mitochondrial Biogenesis 
Mitochondrial biogenesis is the neosynthesis of organelles, involving the 
activation of a collective transcriptional program in response to their systemic 
environment.  Expansion of mitochondrial mass is paralleled by enhanced enzymatic 
activity and often a more networked reticulum.  This process is finely synchronized to 
physiological stimuli, and in the case of skeletal muscle, the foremost effector is the 
presence or absence of contractile activity (59, 141).  Endurance exercise has long been 
known to induce favorable molecular adaptations, including an increased inclination for 
aerobic metabolism (57).  Takahashi and Hood (161) demonstrated that chronic low 
frequency stimulation of the tibialis anterior in rodents gave rise to significant increments 
in mitochondrially-derived enzymes.  Citrate synthase and succinate dehydrogenase 
increased in tandem, along with a substantial increase in the unique mitochondrial 
membrane phospholipid cardiolipin.  These adaptations to chronic contractile activity 
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(CCA), demonstrate that the expansion of the mitochondrial membrane coincides with an 
enhanced enzymatic inclination, and an overall improvement to the bioenergetic profile 
of muscle.  The synchronous increases to such biochemical markers formally define 
mitochondrial biogenesis.   
1.1.1 Regulators of biogenesis : PGC-1α 
During bouts of submaximal exercise, the hydrolysis of ATP at the myosin 
ATPase site of muscle is paralleled by the accumulation of ADP (118).  
Phosphotransferases such as adenylate kinase interconvert ADPs to ATP and AMP, when 
a high [ADP] favors the forward-reaction.  The ensuing accretion of AMP results in the 
activation of AMPK, an energy sensing kinase responsive to states of energy depletion.  
AMPK acts upstream of the activation of peroxisome proliferator-activated receptor 
gamma co-activator 1-alpha (PGC-1α), a known regulator of mitochondrial biogenesis.  
Another biogenesis signaling mechanism involves the co-enzymes nicotinamide adenine 
dinucleotides, NAD
+
 and NADH+H
+
, which provide the electrons fuelling the redox 
reactions of the ETC.  Exercise perturbs the NAD/NADH ratio, and incites the signaling 
pathways preceding the mitochondrial adaptations to exercise.  The deacetylase SIRT1 
consumes NAD
+
, and is also receptive to the exercise-induced fluctuations of the 
substrate.  SIRT1 has been proposed as an important modulator of exercise-mediated 
mitochondrial adaptations.  A decrease in NADH+H
+
, and subsequent increase in NAD
+
, 
especially during prolonged low-moderate intensity exercise, results in the activation of 
SIRT1 and family member SIRT3.  Both have been proposed to invoke mitochondrial 
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biogenesis, with SIRT1 de-acetylating the transcriptional co-activator PGC-1α  (88).   
PGC-1α, identified as a nuclear receptor co-activator, was found to induce the gene 
expression of ETC subunits, mtDNA transcription factors (183) and total mtDNA (140).  
PGC-1α does not bind DNA directly but docks onto transcription factors, exerting 
expressional control over a large subset of metabolic genes (101). The PGC-1α isoform is 
enriched in skeletal muscle, and to the highest degree in oxidative type I fibres (102).  
Further, transgenic expression driven by a muscle-specific creatine kinase promoter in 
mice, resulted in a phenotypic shift to a more oxidative profile of glycolytic fiber types.  
In muscle, the protein induces a broad expression of nuclear-encoded mitochondrial 
genes of interest, including (NUGEMPs) PPARγ, NRF1 and NRF2, ERRα and TFAM (63).  
Transgenic expression in C2C12 myotubes was found to increase maximal rates of 
respiration by 1.9-fold, revealing a positive regulatory effect on ETC proteins  by 
enhancing mitochondrial biogenesis (140).  In humans, acute contractile activity induced 
robust 25-fold increases in PGC-1α mRNA in biopsied vastus lateralis muscle.  
Transcript levels peaked at 2 hours following activity, and corresponded to an increase in 
total mRNA at a later time point (138).  Exogenous expression of the protein in cardiac 
muscle brought on “uncontrolled proliferation” of mitochondria (93), demonstrating the  
potent regulatory control on organelle synthesis.   Knockdown of PGC-1α was found to 
blunt the adaptive responses to chronic contractile activity (CCA) in skeletal muscle cells 
(171), and helped establish PGC-1α as a central player to the exercise-induced 
mitochondrial adaptations.  The local supply of ATP at the myosin ATPase site of 
muscle, must be continually replenished during extended bouts of submaximal intensity 
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exercise.  By modulating oxidative capacity through regulators such as PGC-1α, muscle 
displays an amazing propensity to adapt to physiological demands.  
1.1.2 C2C12 myotubes as a model of CCA  
C2C12 cells are a murine derived cell line that has been extensively used in the 
tissue culture studies of skeletal muscle.  Easily differentiated into excitable muscle cells, 
they are a valuable tool in the study of muscle activity.  The contractile activity 
accountable for musculoskeletal adaptations is mimicked in the in vitro model through 
the application of a controlled voltage.  It has been demonstrated that the molecular 
alterations seen in the trained mouse model are highly reproduced in the cell culture 
model of C2C12 stimulation  (3, 125).   Contractile activity-induced changes to the 
transcriptional profile of in vitro myotubes matched those of a trained mouse model 
(125).  The authors compared low frequency 24 hour electronic pulse stimulation (EPS) 
of cultured myotubes to a 6 week treadmill training regimen in mice.  The PGC-1α 
transcript was found to increase by 2.9-fold in the cell culture model versus an analogous 
2-fold increase in trained mice (18).  In addition to PGC-1α upregulation, Burch et. al 
found a similar upregulation in the expression of TFAM (transcription factor of 
mitochondria) as well as genes of oxidative phosphorylation (OXPHOS), including 
ubiquinol oxidase and Complex I (NADH-ubiquinion subunit 5).  We have previously 
demonstrated that the in vitro model of chronic contractile activity to induce 
mitochondrial biogenesis as evidenced by enhanced enzymatic cytochrome oxidase 
(COX) activity and OXPHOS protein expression (24, 119, 171).  This in vitro model is 
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thus a valuable tool, permitting the controlled study of molecular adaptations to 
“exercise”.   
1.2 Oxidative phosphorylation 
Cellular survival depends on a steady supply of adenosine triphosphate (ATP), 
generated by a sequence of energy coupling reactions in the ETC, located at the inner 
mitochondrial membrane (IMM).  In eukaryotes, the mitochondrial respiratory chain 
exists as a series of electron-shuttling cytochromes, accepting high energy electrons from 
the pyridine nucleotide NADH, and succinate, in a process termed oxidative 
phosphorylation (OXPHOS). The glycolysis product pyruvate, and the β-oxidation of 
fatty acids, yields Acetyl CoA, proceeding to Krebs cycle for the indispensable 
production of co-enzymes NADH and FADH2.  The co-enzymes represent the electron 
donor pool for ATP production at the ETC, ultimately reducing molecular oxygen (158).  
Five multi-protein complexes span the IMM, complexes I through V.  The first enzyme in 
the chain, Complex I (NADH: ubiquinone oxidoreductase), transfers electrons donated 
from NADH to reduce the electron carrier ubiquinone (UQ), embedded in the membrane 
between Complex I and II (7).  Protons are successively transferred from the matrix and 
accumulate in the inter-membrane space, generating a chemiosmotic gradient.  UQ 
provides a point of entry for succinate derived electrons, which are transferred to 
Complex II (succinate dehydrogenase).  Complex III (cytochrome bc1 complex), which 
can both oxidize reduced UQ and accept electrons from Complex I, eventually shuttling 
electrons to Complex IV (Ubiquinol oxidase). Like Complex I, Complexes III and IV 
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transport matrix protons into the inter-membrane space against their electro-chemical 
gradient, establishing the mitochondrial membrane potential (ΔΨm) between the outer 
and inner membranes.  The maintenance of ΔΨm is critical to the bioenergetics of the 
organelle and facilitates to the proton-motive force exploited by the FOF1 ATP synthase 
(Complex V) (180).   This trans-membrane enzyme contains an ion channel permitting 
the flow of protons back into the matrix, coupled with an ATP synthase.  Harvesting the 
free energy released as H
+
 flow back into the matrix, down their electro-chemical 
gradient, Complex V enables the phosphorylation of ADP into ATP.  The complex IV-
mediated reduction of oxygen, acting as the terminal electron acceptor, combines with H 
atoms and condenses to water, and hence, the oxygen consuming pathway is termed 
oxidative phosphorylation (56) (OXPHOS). 
1.2.1 States of respiration 
Cellular respiration  is defined as the oxygen consumption of intact cells (27), 
although largely attributed to both the quantity and functional capacity of mitochondria 
(15), other cellular compartments may also consume oxygen (12) and confound results.  
Unlike mitochondrial respiration, cellular respiration cannot be normalized to 
mitochondrial content making it impossible to delineate conclusions on organelle quality 
(15).  It is therefore necessary, when attempting to gain insight on the discrete respiratory 
quality of the mitochondrial population, to perform measures on fractions of isolated 
mitochondria while correcting for protein content.  In 1955, Chance and Williams 
revealed an effective assay allowing for the quantification of oxidative respiration of 
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isolated mitochondria.  The consumption of oxygen in the process of OXPHOS, and the 
reliance on ADP, were used to deduce the rates of respiration using a known 
concentration of the dinucleotide (27).  Using a platinum electrode inserted into a cuvette, 
the authors were able to monitor oxygen consumption of isolated organelles in response 
to the addition of energy substrates. A slope correlating to the kinetics of oxygen 
consumption was determined, and when dissolved substrates or oxygen were exhausted, 
the slope was equivalent to zero.  When mitochondria are removed from their local 
cellular environment in the process of isolation, they are likewise removed from the 
milieu of substrates allowing for functional respiration.  Exogenous administration of 
substrates into the suspension medium is therefore necessary to evaluate respiratory 
control.  Healthy, intact mitochondria exhibit a tight coupling of ETC reduction reactions, 
to the complex IV-mediated reduction of oxygen, so the utilization of O2 is consequently 
an effective indicator of respiratory control.  Different states of respiration have been 
defined for the in vitro analysis of mitochondria: State IV respiration is oxygen 
consumption on a particular substrate in the absence of ADP, while State III is defined as 
the oxygen consumption in the presence of ADP. 
1.3 Reactive Oxygen species 
 Reactive Oxygen Species are a normal byproduct of OXPHOS.  They are 
generated when high energy electrons fail to complete the ETC and inadvertently result 
in the partial reduction of oxygen. Mitochondrial superoxide (O2
•−
 )  is produced as a 
result of the addition of a single electron to molecular oxygen, and is an important source 
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of intracellular ROS.  Complexes I and III (16) are seen as the canonical sites of ROS 
generation, though recently Complex II has also been implicated (142), depositing the 
oxidizing agents into both the matrix and intermembrane space.  Since the matrix 
contains inherent antioxidant defense systems, matrix-bound ROS are readily quenched 
under model conditions.  Manganese superoxide dismutase (MnSOD) catalyzes the 
reduction of O2
•−
 into H2O2, to be further reduced by glutathione (GSH) and thioredoxin 
(Trx) into water (5).  ROS deposited into the intermembrane space may evade this 
defense and escape through porins into the cytoplasm. When H2O2 levels are high, and in 
the presence of reduced iron (Fe
2++
) or copper (Cu
+
), the molecule engages in Fenton’s 
reaction, producing hydroxyl radicals (●OH), the most volatile class of ROS (167). 
Oxidative stress results when ROS production exceeds the inherent buffering capacity of 
the organelle.  Estimates place ROS generation at 0.2-2% of total oxygen consumption 
during OXPHOS (114).  While the majority of the literature identifies the organelle as the 
primary effector (30, 98, 115, 190), it has been contested for lack of evidence (17).  The 
heterogeneity of intracellular ROS production undoubtedly confounds the determination 
of the organelles relative contribution to cellular oxidants.  Boveris et al. quantified H2O2  
production on isolated fractions of cellular organelles and found that peroxisomes 
generated a maximal 16.4 nmol/min per mg of protein, compared to  0.5 nmol in the 
mitochondrial fraction during state IV respiration (12).  Perhaps the most conclusive 
evidence combined flow cytometry, electron spin resonance (ESR), and fluorescent 
probes with models of cellular stress to evaluate ROS production (86).  Unpaired 
electrons can be effectively detected through ESR using both permeable and 
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impermeable probes.  Intact cells incubated with antimycin A (AntA), a potent complex 
III inhibitor, were found to undergo a 2-fold increase to intracellular ROS.  Further, 
impermeable ESR probes could not detect O2
•− 
emission from control isolated 
mitochondria, but AntA treatment resulted in the significant increase of both intra- 
mitochondrial and emitted ROS.  This evidence corresponded to the whole cell analysis 
under ROS-inducing conditions, using the fluorescent probe, 2’7’dichlorofluorescein 
(DCF) which detects H2O2 preferentially, thus disclosing that under basal conditions, 
mitochondria are not significant sources of intracellular ROS. Conversely, under 
circumstances of OXPHOS disruption and cellular stress, they become prominent cellular 
ROS effectors (86).   
 1.3.1 Inherent antioxidant system: MnSOD 
Aerobic metabolism has the potential to introduce highly reactive oxidants to the 
cellular environment.  Excess unbuffered ROS can lead to nuclear and mtDNA damage, 
the oxidation of proteins, membrane disruption, and can mediate cell death pathways 
through tumor necrosis factor alpha (TNF-α) (129).  Mitochondria possess high 
efficiency inherent oxidant buffering systems.  MnSOD is a nuclear-encoded enzyme 
localized to the matrix, and is the principle quencher of mitochondrial ROS.  Mammalian 
MnSOD exists in tetrameric formation containing a manganese (Mn) core and an N-
terminal mitochondria-targeting sequence.  The transition between Mn
3+
 and Mn
2+  
at the 
active site allows for the protonation of O2
•− 
into hydrogen peroxide  (1).  The activity of 
MnSOD is positively influenced by de-acetylation via SIRT3 in response to cellular 
stress (163).   MnSOD knockout mice die before 3 weeks of age, and knockdowns reveal 
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autophagosome accretion (LC3-II),  with enhanced mitochondrial content (citrate 
synthase activity) (134).  Further, lack of gene function has been purported to deregulate 
autophagy (123), potentially signifying a phenotypic autophagy defect.  A sustained 
reduction in MnSOD was linked to elevated deoxyguanosine, a biomarker of DNA 
oxidation, in both nuclear and mitochondrial DNA, and an upregulation in tumor 
frequency (146).  MnSOD levels may rise as a cytoprotective response to cellular aerobic 
stress (21), and as an adaptive mechanism during endurance training (147). 
1.3.2 Role in pathology  
As a potential therapeutic target, ROS toxicity has become a study of interest, 
found to participate in the pathogenesis of chronic conditions such as diabetes (62, 127), 
cardiovascular (66), neurodegenerative diseases (39), and even cancer (20, 97, 149, 150).  
Excess ROS production is a characteristic of ETC insufficiency (69), and conditions of 
oxygen tension such as hypoxia (108).  mtDNA mutations linked to ROS are a common 
feature of tumor cells, and ROS have been found to contribute to metastatic potential 
(69).  Ischemic and failing hearts display augmented ROS production (91, 145).  The 
etiology of neurodegenerative diseases provides conclusive evidence that ROS are a 
partial contributor to neuronal attrition (44, 74).    
1.4 Fusion and fission 
The distribution and availability of mitochondria in post-mitotic cells is 
contingent on fission and fusion events, critical for the propagation of mtDNA, organelle 
biogenesis and segregation for selective autophagy.  Fusion is a process culminating in 
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the amalgamation of inner and outer mitochondrial membranes, while fission defines the 
reverse phenomenon.  Chronic contractile activity like endurance training, is known to 
lead to adaptive responses in the mitochondrial network, namely the expansion and 
elongation of the mitochondrial reticulum in skeletal muscle (67, 84).   Mammalian 
mitochondrial fusion is mediated by the proteins Mfn1/2 and OPA1, while fission is 
primarily governed by two key polypeptides, dynamin related protein 1 (Drp1) (47), and 
mitochondrial fission protein 1 (Fis1) (177).  Localized to the OMM (47), these proteins 
dynamically regulate mitochondrial morphology by facilitating dissociation from the 
reticulum.  The opposing mechanism of fusion involves the transmembrane GTPase 
Mfn1, when constitutively overexpressed results in hyper-clustered, perinuclear 
mitochondria (148).  Opa1 promotes the association of inner membranes  during fusion 
(36), by operating in conjunction with Mfn1.  Alterations in the ratios of these fusion and 
fission proteins reveal which system is prevailing.  Chronic muscle use was found to lead 
to an increased ratio of fusion: fission proteins, while chronic disuse increased the 
prevalence of fragmented mitochondria and shifted the ratio toward fission (67).  
Electron micrographs of denervated muscle revealed smaller, more fragmented organelles 
within 24 hours (120), communicating the malleable nature of the mitochondrial 
landscape.  This remodeling process is highly responsive to the cellular milieu and 
bioenergetic demand, allowing for maximal cellular efficiency. 
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1.5 Mitochondrial protein import 
Import is vital to the functional integrity of the organelle, and the mitochondrial 
membranes contain discrete modes of entry for substrates and integral proteins.  Porins, 
located on the outer mitochondrial membrane (OMM), facilitate the transport of 
molecules of less than 5 kDa in size, while transport complexes allow for the active 
transport of larger proteins.  The outer and inner membranes contain distinct translocase 
systems, the TOM and TIM complexes respectively, working in a coordinated fashion to 
facilitate the import of newly-translated proteins.  The TOM complex is a collection of 9 
known subunits spanning the outer membrane, individually identified by a unique name 
corresponding to their specific molecular weights (TOM20,TOM40 etc.).  These subunits 
comprise cytosolic receptor domains, and include peptides and proteins that construct the 
import channel (137).  Nuclear-encoded proteins destined for mitochondria are translated 
in the cytoplasm as precursors, and undergo unfolding to achieve their import-ready state 
(99).  These pre-proteins contain positively charged amino-targeting sequences 
recognized by the cytosolic chaperone, heat shock protein 70 (HSP70), and the receptor 
complexes TOM20 and TOM22.  HSP70 mediates the unfolding of pre-proteins in 
preparation for translocation, and is established to be critical for the active transport 
process (100).  Although TOM20/TOM22-mediated import is contingent on an N-
terminal pre-sequence, other proteins containing inherent target sequences can be 
imported through other members of the TOM machinery (TOM37,TOM70). Facilitating 
delivery across the inner membrane, the TIM complexes TIM23 and TIM17 dimerize 
upon the presence of a sufficient membrane potential.  The impending translocation of 
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proteins into the mitochondrion is contingent on ΔΨm (42).  Additional TIM components 
interact with a matrix HSP70 (mtHSP70) allowing for the final transition of the pre-
protein into the mitochondrial matrix driven by ATP hydrolysis.  Before the newly 
imported pre-protein can be folded into its mature protein conformation, the targeting 
sequence is cleaved by the mitochondrial processing peptidase (MPP).  Mitochondrial 
proteases, including LONP1, degrade polypeptides that fail to achieve their tertiary 
conformation (131).   
 1.6 Apoptotic signaling: mPTP opening 
The maintenance of mitochondrial membrane potential (ΔΨm) is critical to the 
bioenergetics of the organelle and overall cellular viability.  Dissipation of ΔΨm can 
result in the initiation of a cell death program known as apoptosis.  Mitochondria play an 
integral role in the regulation of cellular survival by manipulating the translocation of 
inter-membrane mitochondrial proteins into the cytosol.  Kroemer and colleagues 
identified a key apoptotic protein released upon the disruption of ΔΨm, termed the 
apoptotic inducing factor (AIF).  AIF travels to the nucleus where it induces structural 
modifications to chromatin and DNA fragmentation, biomarkers of apoptosis (160).  The 
mitochondrial permeability transition pore (mPTP) is a crucial mediator of cellular 
survival.  By modifying membrane permeability, the pore is able to facilitate the escape 
of pro-apoptotic factors, cytochrome c,  AIF and a number of caspases (109).  Bcl-2 and 
Bcl-XL are key pro-survival polypeptides, with Bcl-XL preferentially expressed in long-
lived cells (11),  while pro-apoptotic proteins Bax and Bak (107) moderate mPTP 
15 
 
opening.  Although a consensus has not been reached on the precise mechanisms of 
apoptotic regulation, the two most accepted arguments involve the heterodimerization of 
Bax with Bcl-2/Bcl-XL thus inhibiting the formation of pro-apoptotic Bax homodimers, 
conversely, Bcl-2/Bcl-XL may suppress cell death in the absence of heterodimerization 
with Bax/Bak (113). ROS has been found to  play a role in apoptotic signal transduction 
when levels exceed the buffering capacity of the organelle (45).  Mitochondrial calcium 
overload is a known inducer of mPTP.  It fosters apoptosis when matrix Ca
++
 is elevated 
(54) through poorly defined mechanisms. In some cell types Ca
++
 chelation attenuated 
ROS-induced apoptosis (48), suggesting that the two conditions converge to impede 
cellular survival.   
 1.7 Mitochondrial DNA mutations 
Mitochondria divide and transmit their genetic information through the process of binary 
fission, with each organelle inheriting multiple copies of a circular genome.  Though the 
mitochondrion is equipped with a proof-reading enzyme, the mutation rate is estimated to 
be at least 10-15 times that of nuclear DNA (38, 53).  Polymerase γ (POLG)  is the sole 
DNA polymerase found in mitochondria, and participates in both the synthesis and base-
excision repair process of mtDNA (111).  Unlike nuclear DNA, mtDNA is not endowed 
with the same repair capacity and lacks protective histones (23), leaving it more 
vulnerable to damage.  mtDNA mutations occur in heteroplasmy (133), as a result of 
heterogeneous clonal expansion.   The most prevalent ETC deficiency occurs at Complex 
I, a feature of Leigh syndrome, and presents with severe anomalies in the CNS causing 
fatality in most cases before the age of 5 (50, 65).  Exercise intolerance is a hallmark of 
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mitochondrial myopathies, caused by mutations resulting in ETC insufficiency (164).   
Mitochondrial myopathy, encephalopathy, lactic-acidosis and stroke-like episodes, 
(MELAS syndrome in short), was characterized in 1985 by Pavlakis et. al, who clustered 
the symptoms as a distinct clinical syndrome (136).  This severe malady includes mental 
retardation and profoundly decreased life expectancy.  An interesting feature of the 
syndrome is the presence of “ragged red fibres” in skeletal muscle as a result of ETC 
defects.  Gene sequencing later revealed that an A to G mutation of the tRNA at position 
3243 (A3243G) of mtDNA is a common feature of MELAS, and maternally inherented 
diabetes and deafness (MIDD) syndrome (133).  The molecular features of MELAS 
include severe enzymatic deficiencies in complexes I and IV with milder impairments to 
complexes III and V (186), systemically distributed among all tissue types.   Some 
evidence suggests that the A3243G mutation disproportionately affects skeletal muscle 
(32).  Since the reliance on oxidative phosphorylation and thus ATP varies considerably 
by tissue type, the manifestation of disease varies accordingly.   Interestingly, the 
majority of mtDNA point mutations encompassing defects of oxidative phosphorylation 
involve mitochondrial tRNAs (124).  Such disorders include the aforementioned Leigh 
syndrome, MERRF, skeletal and cardiomyopathy.  Patients are typically exercise 
intolerant and present with progressive myopathy (89), and episodic symptoms (124).  
Although undiagnosed at the time, it has been proposed that Charles Darwin was afflicted 
with a mitochondrial syndrome caused by a mutation in A3243G, which would explain 
his variable and peculiar symptoms including nausea, muscle-spasms and lethargy.  
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Family lineage studies confirmed maternally-linked symptoms, characteristic of mtDNA 
mutations (55).    
2.0 Degradation / Quality Control Pathways  
 2.1 Ubiquitin and p62 
Autophagy is a catabolic process that involves a series of events commencing 
with the irreparable step of identification, and subsequent degradation of proteins (9).  
Ubiquitin (Ub), an 8.5 kDa protein (152), identified to be a critical component of the 
proteolytic pathway, is highly conserved and expressed in most cell types (179).  
Ubiquitination is a tightly regulated, ATP-dependent process, involving activation and 
conjugation of the peptide to the amino-terminus of lysine residues of target substrates 
(179), often forming poly-Ub chains at several sites.  In 1996, Vadlamudi et. al identified 
p62/SQSTM1 as a novel Ub-binding protein associating with multiple Ub-chains (174).  
E3-ligases are the terminal enzymes in the Ub pathway, requiring the activity of E1-
activating, and E2-conjugation enzymes. The conjugation culminates in the covalent 
addition of Ub to substrate proteins, effectively tagging them for proteasomal 
degradation.  p62 functions to sequester and consolidate target substrates into bodies for 
degradation by autophagy.   Inadequate clearance resulting in the accrual of protein 
aggregates are the hallmark of many degenerative diseases including Alzheimer’s, 
Parkinson’s and some forms of steatohepatitis (188), and coincide with the build-up of 
p62, in addition to other stress-responsive proteins.  The myofibrillar myopathies 
myotilinopathies and desminopathies, resulting from the mutations of genes encoding 
18 
 
contractile proteins, are also characterized by abnormal protein aggregates in muscle co-
localizing with p62 (73).   Free radical-induced oxidation of aggregates further reduces 
the availability of these aggregates to proteolytic digestion (73), and may explain the 
degenerative propensity of the disease.   
2.2 Proteasome system 
An important component of the protein degradation machinery in eukaryotic cells 
is the proteasome.  The catalytic complex was found to be integral to the Ub-conjugated 
proteolysis pathway (117), and present in all mammalian cells.  Two populations of 
proteasomes exist, a larger ATP-dependent 26s proteasome and its smaller 20s ATP-
independent counterpart (61).  It is the 26s proteasome that preferentially targets Ub-
tagged substrates.  The Ub-proteasome and autophagy are two often intersecting cellular 
mechanisms of protein catabolism.  
 2.3 Autophagy proteins and pathway 
Autophagy is a process involving the bulk sequestration and degradation of 
cytoplasmic material in response to cellular stress, metabolic status and pathogen 
infiltration.   Considered a cytoprotective mechanism, inhibition of the process has been 
found to trigger apoptosis (14).  Early evidence of autophagy included the glucagon or 
hypoxia-stimulated encapsulation of cytoplasmic material by a double-membraned 
vesicle, now known as the autophagosome (43).  Ultrastructural studies revealed that the 
autophagosome contained whole organelles and fused to pre-existing lysosomes (43), 
which deliver the digestive enzymes.  Microtubule-associated protein 1 light chain 3 
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(LC3), the mammalian orthologue to the Atg8 protein first documented in yeast (83), was 
established to play an essential role in autophagosome formation.  It was revealed that 
LC3 was distributed in the cytosol under steady-state conditions, and largely responsive 
to starvation, at which time it rapidly associated with the autophagic membrane.  This 
upregulation of autophagy in response to conditions of nutrient-starvation, was shown to 
improve cellular viability (170) by repurposing nutrients for essential cellular processes.  
The identification of LC3 in mammalian cells, and the protein’s interaction with the 
autophagosome membrane (77),  provided novel insights into a largely uncharacterized 
mechanism.  Kabeya et al. (78) conveyed evidence for two distinct forms of the protein, 
LC3-1 and LC3-II, resulting from sequential post translational modifications.  Initially, 
the LC3 precursor undergoes a cleavage of 22 amino acids from its c-terminus producing 
LC3-I, and in this form maintains a cytosolic distribution.  LC3-I is converted to LC3-II 
through conjugation with phosphotidylethanolamine (PE) (78), an indispensable 
lipidation event which facilitates hydrophobic membrane incorporation.  LC3-I and LC3-
II migrate as discrete bands in immunoblot SDS gels, representing the cytosolic and 
membranous forms respectively. Increments to autophagy coincide with enhanced p62 
clearance, whereas the opposite is true for p62 accretion.  Serum starvation gave rise to 
elevated protein expression of LC3-II, and was determined to correspond to enhanced 
autophagy.  Autophagy proceeds sequentially through phases of induction, nucleation, 
elongation and termination.  Upon receipt of the necessary autophagy stimuli, initiation 
events ensue and include the complexing of ULK1, Beclin1 and VPS34 (class III 
phosphoinositide 3-kinase), assisting in early autophagosome formation in the nucleation 
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phase (95).  The proceeding elongation stage encompasses a series of ubiquitin-like 
conjugations, Atg5 conjugates to Atg12, partaking in E3-enzymatic activity, and binding 
Atg16L1 to form a trimeric complex.  Atg16L1 is able to localize the complex with the 
autophagosome membrane, while Atg5-Atg12 interacts with the E2-enzyme Atg3 (132), 
which further conjugates the E1-ligase, Atg7.  The terminal step of autophagy involves 
the Atg3-Atg7 dependent conjugation of Atg8 (LC3) with PE, allowing the membrane 
stabilization of LC3-II and enclosure of the autophagosome membrane.  The mature 
autophagosome is free to bind the lysosome to facilitate the final proteolytic process.   
   2.3.1 Autophagy signaling 
The mammalian target of rapamycin complex I (mTORC1) is the main mediator 
of autophagy in mammals, and when active, exerts an inhibitory effect on the catabolic 
process.  Adenosine monophosphate-activated protein kinase (AMPK) embodies an 
opposing signaling cascade.  AMPK is a key activator of autophagy (82), and this 
metabolic-sensing kinase, is itself phosphorylated on threonine
172
, mediated by an 
increased ratio of AMP:ATP, subsequent to energy depletion. The nutrient-stress 
signaling of AMPK, results in the targeted phosphorylation of raptor at serine
722/792
, 
which exerts an inhibitory effect on mTORC1.  This complex is a critical check-point in 
the initiation and sustainment of anabolic processes such as protein translation, the 
expression of translation machinery, and cell-cycle progression (22), thereby ensuring 
that the current metabolic status meets the requirements for growth.  Proliferative events 
are impeded by mTORC1 inhibition, allowing mammals to systemically modulate growth 
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and non-essential cellular processes in response to poor energy-status.  In this way, multi-
level cellular regulation is fine-tuned to changing physiological and environmental 
conditions, and favors survival.  Another cytoprotective response to transient and 
sustained energy-deprivation is the catabolic process of autophagy.  The dependence of 
macroautophagy on nutrient availability was illustrated by the studies of Hutson and 
Mortimore, who recognized that the loss of amino acids was a potent catabolic stimulus 
upregulating the autophagic localization of cytosolic aggregates (64).  Rapamycin, an 
mTORC1 inhibitor, inactivates the complex and mimics the effect of nutrient depletion 
by enhancing autophagy (182).  During nutrient sufficiency, mTORC1 is active and 
exerts inhibitory control on downstream regulators to block autophagy.  Despite the fact 
that nutrient depletion was identified as a potent stimulator of autophagy nearly half a 
century ago, the precise mechanisms modulating the canonical nutrient sensing pathways 
remain obscure.  One model proposes that the activated mTORC1 phosphorylates 
TAP42, causing association of the protein with PP2A (phosphatase 2A) (185).  Bound to 
TAP42, the activity of PP2A is sequestered, impeding the de-phosphorylation of its 
target, Atg13 (187).  The resulting hyper-phosphorylated state of Atg13 prevents its 
localization to ULK1 and the initiation of autophagic events (116).  Upon nutrient duress, 
PP2A action is re-instated, the hypo-phosphorylated Atg13 can interact with ULK1, and 
autophagy inhibition is lifted.  Thus, the phosphorylation status of Atg13 is mediated by 
the metabolic signaling through mTORC1, and regulates the catabolic pathway.  
Alternatively, AMPK can directly activate ULK1 at two phosphorylation sites, while 
active mTORC1 can exert an inhibitory phosphorylation on ULK1 (82).  The mammalian 
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homologue to the S. cerevisiae protein Atg1, ULK1, is at a pivotal interrogation point to 
the suppression or commencement of autophagy and characterizes the induction phase.  
Nuclear factor-kappa B (NF-κB), a pro-survival transcription factor with an expansive 
range of gene targets including those of apoptosis, proliferation and differentiation (169), 
was found to be a negative regulator of autophagy by repressing TNF-α (40).  In contrast, 
constitutive expression of TNF-α, a pro-apoptotic cytokine, resulted in a drastic 
increment in autophagy in human myocytes (81).  Muscle wasting in models of disuse 
was found to enhance muscle ubiquitination, through increased expression of the muscle 
RING-finger protein-1 (MURF-1).  This effect was blocked by targeted antioxidant 
administration (162), implicating ROS in disuse-mediated autophagy.  Contractile 
activity, like exercise, can mimic the metabolic signaling of nutrient disparity, and has 
been found to activate autophagy in skeletal muscle (51, 71, 105).  
2.3.2  ROS-mediated autophagy 
Emerging evidence suggests ROS as key mediators of skeletal muscle autophagy.  
C2C12 cells were subjected to well-established inducers of autophagy, nutrient 
deprivation and rapamycin, and acute treatment resulted in elevations in ROS and LC3 
lipidation.  Incubation with both mitochondrial-specific antioxidants and NAC pointedly 
reduced LC3-II, and reduced the expression of autophagy proteins.  This evidence 
successfully validated ROS as a critical upstream autophagy effector (143).  Similarly, 
exogenous H2O2 administration resulted in a heightened autophagic response (40, 92), 
and enhanced p62 degradation (92), whereas antioxidant treatment diminished basal 
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autophagy (172).  ROS are dominant inducers of AMPK activation  (34, 68, 143, 168, 
181), and genetic ablation of the kinase compromised autophagy in a ULK1 dependent 
manner (41).  The Atg1 homologue was identified to be an AMPK substrate containing 
four phosphorylation sites including the conserved sites Ser
555,574
.  ULK1 
phosphorylation at Ser
555
 was induced by both phenformin-mediated complex I inhibition 
and constitutively active AMPKα1 expression (a subunit of AMPK) (41), indicating the 
AMPK-mediated phosphorylation of ULK1 is responsive to mitochondrial respiratory 
distress.  Further, ROS stimulated AMPK activity can exert its canonical influence 
through mTORC1 inhibition (29), providing an additional mode of autophagy control.  
 2.4 Autophagy flux 
Autophagy is a dynamic process which fulfills the essential role of organelle and 
protein turnover within the cell.  When autophagy is elevated, LC3-II incorporation into 
the autophagosome is likewise enhanced, and eventually subjected to proteolysis 
alongside autophagosome cargo, consequently resulting in the rapid decomposition of 
LC3-II under normal conditions.  During pathological states ensuing in autophagy 
deficits, or when the requirement for autophagy overwhelms cellular capacity, LC3-II 
levels can accrue.  Thus, an increase in LC3-II can paradoxically reflect an upregulation 
of the process, or a decrement in its clearance, presenting a  challenge in generating 
inferences on this dynamic process (122).  Autophagasome substrate delivery to the 
lysosome, including upstream events, is herein referred to as autophagic flux.  The study 
of mammalian autophagy has been aided by the development of approaches that decipher 
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the limitations in assessing autophagic flux.  Reliable studies often include multiple 
approaches in flux valuation including fluorescent visualization of the LC3 expression 
vector (77), and chemical interventions that arrest autophagic flux are required to 
accurately gauge its progression.  Pharmacological inhibition of autophagic flux can be 
compared across conditions, if an arrest in degradation confers an additive response to 
LC3-II, this is translated to elevations in flux (122).  Downstream inhibitors of autophagy 
such as lysosomal pH neutralizers BafA and chloroquine, are commonly used to 
determine flux (25).  The Ub-scaffold protein p62 co-localizes with protein aggregates, 
and must be assessed in corroboration with LC3 to accurately gauge autophagic flux.  
The protein which allows for the sequestration of LC3, is degraded alongside autophagic 
substrates, and reduced levels are reflective of enhanced clearance and vice versa.   
2.4.1 Autophagy inhibition 
Pharmacological and genetic approaches have both been described that effectively 
inhibit autophagy through a variety of mechanisms.  Autophagy inhibitors that target the 
lysosome include bafilomycin A1 (BafA) and chloroquine.  Both agents result in an 
increased lysosomal pH.  BafA inhibits the vacuolar type  H
+ 
 ATPase (V-ATPase) 
shuttle that allows for the translocation of protons into the lysosome, while chloroquine 
diffuses directly into the lysosome and consumes H
+
 through oxidation.  Since the fusion 
of autophagosome and  lysosome are pH dependent (80), these agents exert their effects 
by thwarting a critical phase of autophagy.  The compounds 3-methyladenine (3-MA) 
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and wortmannin inhibit phosphotidylinositol-3-kinase (PI3K), required for 
autophagosome formation (70), and inhibit early autophagy.   
   2.4.2 Bafilomycin A1 alternate effects 
 Bafilomycin A1 is an antibiotic derived from Streptomyces.  It was  determined to 
be a highly specific inhibitor of V-ATPases, and exerts no effect on the mitochondrial 
FOF1 ATP ase (13).  This macrolide averts the acidification of lysosomes, a prerequisite 
for the fusion and formation of autolysosomes (184).  At high concentrations (>150 nM), 
BafA has been reported to exert K
+ 
ionophoric effects, contingent on K
+ 
availability of 
the incubation media. The resulting potassium influx permits a mild swelling of 
mitochondria.   In addition, decrements to ΔΨm were observed in a dose-dependent 
manner and only when concentrations exceeded 150 nM, and attenuated mitochondrial 
respiration (166).  Concentrations ≥10 nM exerted an inhibition of cell growth and 
survival (58).  At extreme concentrations (10 μM), the agent resulted in significant 
acidification of the cytosol (10). In adipocytes, BafA  (400-800 nM) stimulated Glut4 and 
Glut1 translocation through the activation of PI3K (33).  Some studies suggest the 
compound exerts a cytoprotective response against chloroquine-mediated apoptosis 
(154).  Most off-target BafA effects are reported at concentrations exceeding 100nM and 
transpire in a dose-dependent manner.  The compound remains a potent, widely used, and 
specific inhibitor of autophagy at lower concentrations.   
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 2.5 Mitophagy  
Mitochondrial degradation and turnover is termed mitophagy, involving the 
selective identification and targeting of the organelle for lysosomal proteolysis.  
Mitophagy is an integral process allowing for the clearance of compromised and 
senescent mitochondria, and critical for conservation of cellular energetics and survival.  
Selective autophagy is a fairly recent proposal; it was long believed that autophagy was a 
non-specific macro process involving the bulk degradation of cytoplasmic components.  
The first evidence for the selective autophagy of mitochondria was the extensive loss of 
the organelle in the maturation of erythroid cells (153).  Schweers et. al,  provided novel 
evidence for the discrimination of targets in autophagic pathways.  Pulse-chase 
experiments involving the sequential incorporation of 
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estimate the half-life of 
mitochondria at 1.8-3 days in liver cells (104, 121).  Mitochondrial clearance and 
regeneration rate are known to be responsive to biochemical and physiological 
perturbations.  Classical studies reveal that the availability of mitochondria in tissue is 
highly volatile, rapidly responding to physiological stimuli (4).  Dietary restriction was 
found to reduce the half-life by 60% (121).  Likewise, cold acclimation enhances 
metabolic rate and elicited enhanced organelle turnover.  Mitophagy-evoking stimuli 
include organelle injury, mtDNA damage (156) and depletion (112), hypoxia (106), and 
perhaps the most potent is the loss of ΔΨm (178). This quality control mechanism is 
integral to the fitness of clonal mitochondrial progeny, since the organelles divide and 
transmit their genome through binary fission.  Mild oxidative stress was found to trigger 
mitophagy, independently of macro-autophagy, implicating mitochondrial dysfunction as 
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the driving-force for clearance (46).  It is suggested that by sequestering defective and 
senescent organelles, such as those emitting excess ROS, mitophagy can curtail the 
deleterious oxidation of proteins, lipid membranes, nuclear and mtDNA.   
  2.5.1 Evidence for selective mitophagy 
The Bcl-2-related protein, NIX, was first described for its critical role in the 
purging of mitochondria from reticulocytes, which in the process of maturation undergo a 
complete loss of the organelle.  The precise mechanism by which NIX arbitrates 
mitophagy has yet to be defined, however, genetic ablation was found to prevent 
mitochondrial localization to the autophagosome (153) thereby mediating mitochondrial 
clearance.  Nix strongly co-precipitates with the key autophagosome protein LC3 when 
cells are treated with the mitochondrial uncoupler CCCP (128), demonstrating that the 
protein promotes mitophagy in an LC3-dependant manner.  NIX contains a C-terminal 
mitochondrial-targeting sequence (28), and an LC3-binding motif (128), corroborating a 
role in the cargo-selection of mitochondria to the autophagosome.   
  2.5.2  Mitophagy proteins: PINK1 and Parkin 
 Originally identified as a tumor suppressor, PTEN-induced putative kinase 1 
(PINK1) levels are down-regulated in ovarian tumors (173). Genome mapping has since 
identified PINK1 to be mutated in homozygous early onset hereditary Parkinson’s 
disease (PD) (175).  PD is characterized by neural degeneration in the post-mitotic cells 
of the substantia nigra.  The pathogenesis of PD is far from clear-cut, though it has been 
linked to mitochondrial dysfunction through mild Complex I and ubiquinone deficiency 
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(151), together with elevated markers of oxidative stress (189).  The progressive course 
of the disease suggests the gradual accumulation of metabolic disturbances.  PINK1 is a 
mitochondrial serine/threonine kinase, with a dense expressional profile in brain, muscle 
and testes (165).  Normally, the 66 kDa full length PINK1 (PINK1FL)  is imported into 
the mitochondrion where it undergoes  rapid proteolytic cleavage by rhomboid 
protease presenilin-associated rhomboid-like protein (PARL), a matrix protease, yielding 
a 51 kDa fragment (PINK1Δ1) (75).  However, upon the dissipation of  ΔΨm, PINK1 
stabilizes on the outer mitochondrial membrane (OMM) (85), where it forms a complex 
with TOM70 (90).  Pulse-chase studies depict the half-life of PINK1FL at 27 min.  The 
cleaved PINK1Δ1 was detected within 3 min, with a half-life of 30 min, which was 
markedly reduced following mitochondrial uncoupling.  Co-immunoprecipitation of 
PINK1Δ1 with the matrix chaperone HSP90 was similarly diminished with OXPHOS 
uncoupling.  A concomitant increase in the stability of PINK1FL was observed (103), 
signifying a shift in the localization of the protein in response to the functional status of 
the organelle.  The OMM localization of PINK1FL  in conditions of mitochondrial duress 
allows the protein to exert its biochemical phosphorylation activity. The kinase has a 
number of known mitochondrial targets including TRAP1 (139), Parkin (155), MIRO (6), 
and Mfn2 (31), with ensuing downstream mitophagy events.  In the absence of PINK1, 
mitophagy inactivation arises, leading to increased apoptotic cell death in the face of 
mitochondrial stress (94).  During elevated oxidative stress, PINK1 suppresses the release 
of cytochrome c, averting apoptotic stimuli and conferring a cytoprotective role (139), 
further illustrating that mitophagy is a critical process mediating overall cellular 
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homeostasis.  This effect was found to be directed by the phosphorylation of the TNF-
receptor protein (TRAP1/Hsp75) (139).  Interestingly, PINK1
-/-
 animals fail to develop 
appreciable levels of neurodegeneration and CNS disturbances as seen in PD.  However, 
they do display impaired pre-protein (OTC) import, severe mitochondrial respiration 
deficits and diminished body weight (49).  Advancing age exacerbated mitochondrial 
dysfunction, and PD-like symptoms developed in the absence of neural atrophy (49).  
Loss of PINK1 gene-function was linked to diminished mtDNA levels, swollen vacuous 
mitochondria, and coincided with drastic reductions in ATP content (135).  PINK1 
mutants are more vulnerable to oxidative stress-induced apoptosis than their wild-type 
counterparts (139), and display defects in Complex I and IV (52).  Interestingly, the 
kinase is believed to function as a mitophagy sensor, arbitrating a multi-tiered 
mitochondrial quality control mechanism, through import, mitophagy, and fission (35).  
PINK1 accretion on the OMM is required for the enlistment of Parkin and Beclin-1 (94). 
Parkin is recruited by PINK1, in part through an association with Fbxo7 (19), and is 
subsequently phosphorylated on serine
65
 (85).  It has been proposed that the voltage-
dependent ion channels located on the OMM (VDACs 1-3) constitute a Parkin docking 
site on compromised organelles (159).  Parkin directs the post translational modifications 
of protein stability through E3-ubiquitin ligase activity.  Mitochondrial ubiquitin ligase 
activator of NFKB 1 (MUL1), was identified in muscle and exerts a similar mitophagy-
promoting mechanism (110).  Although an interaction between PINK1/Parkin and Nix 
has yet to be characterized, Nix-dependent mitophagy was preceded by necessary Ub-
conjugation events (153).  The integrated mitochondrial network or reticulum is protected 
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from autophagy (144), and orchestrated by the fusion proteins, Mfn1/2.  Mitochondrial 
injury and OXPHOS failure, heightens the proteolysis of the OMM fusion proteins, in a 
Parkin-dependent manner (52).  Dissociation from the mitochondrial reticulum, and 
sequestration of the organelle are obligatory phenomena preceding the autophagy 
cascade.  To such a degree, OMM remodeling imparts a potent stimulus for  mitophagy 
(26, 94, 191).  In addition, PINK1/Parkin may regulate selective ETC protein turnover 
autonomously of mitophagy.  Vincow et. al, demonstrated that both PINK
-/- 
and Parkin
-/- 
animals presented decreased turnover rates of ETC subunits, and to a greater extent than 
autophagy Atg 7
-/-
 mice (176).  Thus, these findings suggest the proteins play a 
supplementary role in the maintenance of ETC components independent of mitophagy.  
Recently, Youle and colleagues reported a novel stimulus for the induction of mitophagy, 
that of mitochondrial unfolded protein aggregation.  Activation of the  PINK1 Parkin 
pathway worked to enhance mitophagy and reduce the protein load irrespective of  ΔΨm 
(76).  In light of the evidence, mitophagy discloses a critical mechanism in mediating 
cellular energetics and survival. 
  2.5.3  Mitophagy signaling 
 Forfeit of mitochondrial ΔΨm is a potent initiator of the mitophagy cascade (87, 
178). The pharmacological ionophore carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) disrupts OXPHOS and ΔΨm, and is universally used to induce mitochondrial 
uncoupling.  CCCP was demonstrated to drive mitophagy through an inhibition of 
mTORC1, in an AMPK-independent manner (87).  ROS are another stimulator of the 
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quality-control pathway.  Over-expression of MnSOD blocked the onset of mitophagy 
(178).  In the presence of mitochondrial-specific antioxidants SS31 and mito-tempol, 
rapamycin and nutrient deprivation of C2C12 myotubes fail to initiate autophagy (143).  
ETC deficient ρ  ۫  cells exhibit low levels of endogenous ROS and in response to 
starvation, fail to commence mitophagy (96).  ROS was found to activate AMPK and 
inhibit mTORC1 (95, 142), elucidating the mechanisms of autophagy induction.  
Accordingly, ROS are materializing as significant modulators of mitophagy.   
2.5.3.1 Skeletal muscle and contractile activity 
Muscle is primarily comprised of long-lived post-mitotic cells.  Since the 
intracellular components such as mitochondria and contractile proteins are relatively 
short-lived, quality control mechanisms dictate their turnover.  The responsiveness of 
mitophagy to metabolic state is a fairly recent area of study, due in part to its recognition 
as a selective process and the identification of mitophagy-specific proteins.  The 
NAD
+
/NAD
+
H
+
 ratio is an indicator of cellular energy status, and energy depleting 
conditions like exercise lead to a relative increase in NAD
+ 
levels.  Cells treated with 5 
mM of the metabolite exhibited LC3 punctae and enhanced mitochondrial fragmentation, 
suggesting an upregulation of  mitophagy in response to metabolic status through 
activation of SIRT1 (72).   
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2.5.3.1.1 Muscle wasting 
Mitophagy initiation is enhanced following denervation, an experimental model 
of muscle wasting (130).  This activation is thought to be secondary to  mitochondrial 
functional decrements (State III and State IV respiration), hindered import, increased 
ROS production (157), and fragmentation (67).  When mitochondrial elimination occurs 
in the absence of organelle synthesis, as is in the case of disuse, there is a net loss of the 
organelle  (2, 130) and mtDNA (79).  Suppression of the mitochondrial ubiquitin ligase 
MUL1 was found to attenuate muscle wasting in response to disuse (110), providing 
evidence that deregulated mitophagy can contribute to pathological muscle atrophy. 
 2.5.4  Mitophagy in pathology  
The cytoprotective properties of mitophagy involve elimination of dysfunctional 
organelles from the mitochondrial pool. An upregulation of mitophagy is seen in patients 
with Choline kinase β mutations (CKB).  The condition results in congenital muscular 
dystrophy, progressive muscle wasting and enlarged mitochondria lacking enzymatic 
capacity.  CKB patients exhibited enhanced expression of PINK1 and Parkin, alongside 
autophagy transcripts LC3 and p62 (126).  Mitophagy appears to be a compensatory 
mechanism for curbing mitochondrial dysfunction, but may become deregulated in 
pathophysiological conditions.  Mitophagy decrements proceed induced pressure-
overload in models of the failing heart (4), and may underlie organelle dysfunction in 
cardiovascular disease.  Mitophagy depression is seen in both senescent animals and in 
pharmacologically-induced heart failure, and has been ascribed to the activity of tumor-
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suppressing p53.  Cytosolic p53 was recently found to sequester Parkin, impeding its 
mitophagic activity and organelle clearance.  p53
-/-
 displayed resistance to mitophagy 
inhibition and displayed a preservation of cardiac functions relative to controls (60).  The 
evolutionary-conserved process of mitophagy is a critical mechanism mediating the both 
the quality of the mitochondrial pool and global cellular survival. 
 
Study Objectives 
The mechanisms and regulators of mitochondrial biogenesis in muscle have been 
well recognized and defined.  Conversely, little is known about the processes that govern 
organelle degradation, mitophagy, in skeletal muscle.  In light of the fact that mitophagy 
and biogenesis interplay to mediate mitochondrial turnover, we set out to determine how 
the two divergent processes interplay.  Applying an in vitro model of mitochondrial 
biogenesis, chronic contractile activity (CCA) (24, 171), our goal was to assess the role 
of mitophagy in shaping the integrity and overall content of the mitochondrial pool.  In 
other words, to illuminate the role of autophagy in regulating mitochondrial quality in 
muscle cells.  Through the use of lysosomal inhibitors to perturb mitochondrial clearance, 
we sought to investigate mitophagy as a determinant of mitochondrial integrity during 
CCA.  Multiple biochemical measures of mitochondrial activity and quality were used to 
gain insight into the functional consequences of mitophagy inhibition.  Fluorescence 
microscopy was employed to validate the autophagy protein data, and provide insight 
into mitochondrial morphology.  Further our goal was to investigate the molecular 
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mechanisms governing this quality control pathway in muscle cells, by evaluating the 
expression of mitophagy-related genes.  By performing comprehensive assessments of 
mitochondrial quality, we hope to gain novel data on the mechanistic role of mitophagy 
during contractile-induced biogenesis in skeletal muscle.  We hypothesized that 
autophagy would be  upregulated in skeletal muscle following contractile activity, as a 
result of enhanced protein turnover indispensible for muscle remodeling.  In addition to 
an enhanced state of autophagy, we hypothesized a similar increase in the process of 
mitophagy, coinciding with  mitochondrial biogenesis.  By impairing mitophagy through 
lysosomal inhibition, we predicted an ensuing accumulation of superfluous organelles 
with diminished respiratory capacity, an effect we expect to moderate with CCA.   
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Fig. 1: Mitophagy protein interactions on the outer mitochondrial membrane (OMM).  
Mitochondria participate in a multifaceted quality control mechanism, mediating the 
turnover of senescent and aberrant organelles.  Organelle dysfunction coincides with 
excessive reactive oxygen species (ROS) production as a result of electron transport 
chain insufficiency.  Elevated ROS contribute to pathology through oxidative damage 
and potentiate further loss of ΔΨ
m
.  Outer-membrane proteins play an integral role in 
the initiation and commitment to a mitophagy signaling cascade.  Normally, PINK1 is 
imported into the inner membrane for PARL-dependent cleavage.  Upon the loss of 
membrane potential (ΔΨ
m
), PINK1 accumulates on the OMM recruiting Parkin by an 
unknown mechanism. PINK1 phosphorylates TRAP1, suppressing mPTP opening and 
apoptosis under mitochondrial stress.  Parkin, an E3-ubiquitin ligase, targets OMM 
proteins for degradation via the proteasome.  Proteasomal degradation of OMM protein 
results in the remodeling of the outer membrane identifying organelles for mitophagy.  
LC3-II contributes to the elongation pre-autophagosome membrane in early mitophagy 
and bulk autophagy, and p62 and BNIP3L participate in cargo-selection and recruitment 
of LC3-II.  Mitochondria destined for proteolysis are enveloped in a double-membrane 
autophagosome and proceed to lysosomal degradation in the final steps of mitophagy.  
BafA treatment inhibits lysosomal activity and thus, prevents autophagy.  CCA induces 
mitochondrial biogenesis and may restore autophagic flux with autophagy inhibition. 
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  Abstract 
Autophagy is a critical survival mechanism facilitating protein turnover and 
pathogen defense in post-mitotic cells in a lysosomal-dependent process.  More recently, 
mitophagy has been identified for arbitrating the selective recognition and targeting of 
aberrant mitochondria for degradation.  Mitochondrial availability is the net result of 
mitochondrial catabolism via mitophagy and organelle biogenesis.  Although the latter 
process has been well described, mitophagy in skeletal muscle is less understood, and it is 
currently unknown how these two opposing mechanisms converge during contractile 
activity.  We have previously reported that chronic contractile activity (CCA) of C2C12 
myotubes in cell culture, reduced mTORC1 activation, a negative regulator of autophagy, 
suggesting enhanced autophagy activation with CCA.  In the presence of a specific 
autophagy inhibitor Bafilomycin A1 (BafA), mitochondria exhibited severely 
compromised state 3 and state 4 respiration, along with increases in reactive oxygen 
species (ROS) production, LC3-II levels and mitochondrial p62.  As previously 
demonstrated, CCA resulted in an approximately 2-fold increase in mitochondrial COX 
activity and COXIV protein.  In the current study, CCA enhanced mitophagy gene 
expression, and ameliorated BafA-induced mitochondrial dysfunction, recovering 
respiration and ROS levels back toward control levels.  CCA led to a 50% decline to 
LC3-II in the presence of BafA, which precisely emulated the reduction observed with N-
acetylcysteine (NAC), antioxidant administration. Thus, we reason the CCA-induced 
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normalization of autophagy occurred through a reduction in oxidant-stress.  These 
findings indicate that contractile activity stabilizes autophagy flux through a reduction in 
oxidative stress and an amelioration of mitochondrial dysfunction, and may represent a 
therapeutic intervention to autophagy deregulation by improving mitochondrial and 
muscle health. 
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Introduction  
Endurance exercise has long been known to evoke favorable molecular 
adaptations, including an increased inclination for aerobic metabolism in skeletal muscle 
(18), and conveys a potential therapeutic intervention to muscle wasting (12) and 
myopathy (56).  Chronic contractile-activity (CCA) in skeletal muscle activates a 
collective transcriptional program of oxidative relevant genes mediated via the  PPARγ 
co-activator 1α (PGC-1α) (52), upregulating features of antioxidant defense (54) and 
imparts resistance to catabolic stimuli in muscle (11).  
Autophagy mediates a pro-survival mechanism via the catabolism of intracellular 
proteins and pathogens in long-lived post-mitotic cells.  Substrates are sequestered in 
double membranous structures eventually fusing with the lysosome for hydrolytic 
digestion of autophagic cargo.  Selective autophagy is a newly implicated branch of the 
catabolic process, involving the discrimination of substrates, usually membrane-bound 
organelles, and in the case of mitophagy, a series of events that identify and localize the 
mitochondria to the autophagosome.  Recently, dysregulation of selective autophagy has 
sparked interest for its role in the pathophysiology of  Parkinson’s disease (57),  
cardiomyopathies (1), and cancer (22, 26, 53).  Beyond their bioenergetic role of 
oxidative phosphorylation (OXPHOS) in eukaryotic cells, mitochondria can radically 
modulate cellular homeostasis.  Aberrant mitochondria participate in cell fate decisions 
by initiating apoptotic pathways (43), facilitate proinflammatory signaling (40) and 
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disrupt cellular redox status by elevating reactive species (ROS) production (19, 25, 35).  
Thus, mitophagy mitigates apoptotic signaling (48) and tempers cellular stress responses 
by evoking indispensable quality control.  Since mtDNA is transmitted through binary 
fission and is estimated to be 15-fold more vulnerable to oxidant insult and mutations 
than nuclear DNA (8, 15), the selective degradation of perturbed organelles ensures 
fitness of the mitochondrial progeny.  Mitophagy stimuli include ETC abnormalities (42), 
mtDNA damage (47), hypoxia (30), and dissipation of the membrane potential (ΔΨm) 
(55).   
PTEN-induced putative kinase I (PINK1), is a conserved serine/threonine kinase, 
possessing an N-terminal mitochondrial targeting sequence (59), with a dense 
expressional profile in brain, muscle and testes (49).  The kinase is believed to function 
as a mitophagy sensor, arbitrating multi-tiered mitochondrial quality control mechanisms, 
through import, mitophagy, and fission (6).  PINK1 recruits the E3-ubiquitin (Ub) ligase 
Parkin in a ΔΨm-dependent manner, in association with Fbxo7 (4), during depolarization 
events.  Parkin-mediated ubiquitin modification provides a binding scaffold for the 
autophagy adaptor SQSTM1/p62 (37), and primes mitochondria for degradation 
independently of the canonical Ub-proteasome system.  The microtubule-associated 
protein 1 light chain 3 beta (LC3b) undergoes post-translational modifications to produce 
two distinct isoforms LC3-I and LC3-II (24).  Cytosolic LC3-I is covalently bound to 
phosphotidylethanolamine (PE) converting it to LC3-II, a critical lipidation event 
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involving Atg7/Atg3 conjugation events, permitting the maturation of the autophagosome 
(41).  Targeted substrates are tethered to the autophagosome by means of an LC3-II 
binding motif on the p62 adaptor protein (27).  Localization of the mitochondria to the 
autophagosome is conditional on the Bcl-2 associated protein NIX, a specific inducer of 
mitophagy (39).   
Mitochondrial ROS (44) and exercise (45) are potent activators of AMPK in 
skeletal muscle, an energy sensing kinase, shown to induce autophagy in skeletal muscle 
with activation (44).  Several studies have demonstrated an upregulation in bulk-
autophagy concomitant to the physiological adaptations to exercise (10, 14, 21, 36) in 
muscle.  Mitochondrial availability is a function of the balance of organelle synthesis and 
mitophagy.  Surprisingly, understanding of how these two mechanisms converge to 
regulate organelle content remains obscure.  Emerging evidence  in humans suggests that 
mitophagy is downregulated with ageing and inactivity, and modified with acute activity 
(9).  A decrement in this process may underlie functional deficits of muscle function with 
age.  We have previously demonstrated that mitophagy markers are upregulated in 
response to acute exercise (46), but little is known about the implications of autophagy 
suppression on mitochondrial function and in response to contractile-activity.  In this 
study, we sought to investigate whether contractile activity could offset the mitochondrial 
insults induced by defective clearance, and hypothesized that mitophagy activation would 
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be elicited concomitantly with the adaptions to contractile activity to enhance 
mitochondrial turnover, and improve mitochondrial function.  
 
Methods 
Cell culture -  C2C12 murine myoblasts (ATCC, Manassas, VA) were proliferated on six-
well and 10 cm culture dishes coated with 0.1% gelatin in Dulbecco's modified Eagle's 
medium (DMEM) (Wisent, St-Bruno, QC) supplemented with 10% FBS (Thermo 
Scientific, Waltham, MA) and 1% penicillin-streptomycin (P/S).  At 90–95% confluency, 
differentiation into myotubes was induced by replacing growth medium with DMEM 
supplemented with differentiation media (DM) containing 5% heat-inactivated horse 
serum (Invitrogen) and 1% P/S.  DM was replenished daily for 4 days until fully 
differentiated myotubes were observed.   
 
Stimulation of muscle cells to induce chronic contractile activity -  Lids from plastic 
six-well and 10 cm dishes were fitted with two platinum wire electrodes such that lengths 
ran parallel to each other at opposite ends, and when placed in the dish become 
submerged in media.  Fully differentiated myotubes were subjected to electrical 
stimulation-induced contractile activity in a parallel circuit attached to a stimulator unit at 
a frequency of 5 Hz and an intensity of 9 V, chronically for 3 h/day over 4 successive 
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days beginning on day 4 of differentiation.  This stimulation protocol has been previously 
described in detail (7)    ifferentiation medium was replenished 1 h prior to stimulation, 
containing vehicle (anhydrous ethanol) or 3 nM  afilomycin A1 ( io hop, ON,  anada)   
 timulation was performed at 37 C and 5% CO2, and the media was replenished 
following stimulation across all conditions.   
NAC treatment-  C2C12 myoblasts were differentiated as described above.  On day four 
of differentiation, media was supplemented with one of four conditions, vehicle, 10 mM 
N-Acetyl-L-cysteine (NAC; Sigma-Aldrich), 3 nM BafilomycinA1 (BafA), or 10 mM 
NAC plus 3 nM BafA.  Media containing the indicated concentrations was replenished 
daily.  Following 24 and 72 hours of treatment, cells were lysed as described and the 
supernatant fraction was used for immunoblotting analysis.   
 
Mitochondrial isolation-  Mitochondria were isolated from myotubes in tissue culture 
using an adapted protocol (32) via differential centrifugation.  Briefly, myotubes grown 
in 10cm plates were washed 2x in ice-cold PBS and scraped on ice using rubber 
policemen in mitochondrial isolation buffer (MIB; 10% 0.1 M Tris-MOPS, 1% EGTA-
Tris, and 20% 1 M sucrose, pH 7.4).  Cells were pelleted at a centrifugation speed of 600 
g (Beckman JA25.5) for 10 minutes at 4ºC and pellets were resuspended in 3 ml of MIB 
on ice.  Suspensions were transferred to chilled 15ml glass potters and subjected to 
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homogenization with an Elvehjem PTFE Tissue Grinder (Wheaton, NJ, USA) at 800 rpm 
for 35 strokes.  Homogenates were transferred to fresh isolation tubes and recentrifuged 
at 600 g.  The supernatant fractions containing mitochondria and cytosol were collected 
and passed through a 40 μm filter (BD Falcon) and the pellet discarded.   Filtered 
homogenates were centrifuged at 9,000 g for 10 min and the resulting mitochondrial 
fractions were resuspended in 500 μl of MI  and transferred to 1.5 ml Eppendorf tubes.  
The mitochondrial pellets were subject to a final wash-spin in a microcentrifuge at 9,000 
g for 10 min, the supernatants were discarded and the pellets were resuspended in a final 
volume of 120 μl of MIB.  Fresh mitochondria were used immediately for respiration and 
ROS assays.    
 
Mitochondrial Oxygen Consumption – Fresh mitochondria (100 μl) were incubated with 
200 μl of VO2 buffer (250 mM sucrose, 50 mM KCl, 25 mM Tris base, and 10 mM 
K2HPO4, pH 7.4), and oxygen consumption was measured at 30°C with continuous 
stirring in a Clark electrode respiratory chamber (Strathkelvin Instruments, North 
Lanarkshire, Scotland) in the presence of 10 mM glutamate to assess state 4 respiration, 
followed by glutamate plus 0.44 mM ADP to elicit state 3 respiration.  NADH addition 
during state 3 respiration was used to evaluate the integrity of the inner mitochondrial 
membrane.   
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ROS detection-  Mitochondrial levels of RO  were quantified using 2’,7’ 
dichlorodihydrofluorescein diacetate (D2DCFDA; Sigma-Aldrich, St. Louis, MO).  When 
oxidized, the compound is converted to the highly fluorescent DCF, with an emission 
spectrum between 480-520 nm, proportional to levels of RO    Mitochondria (75 μg) 
were isolated as described and incubated in VO2  buffer and D2    A for  45 min at 
37 , with glutamate (state 4) or glutamate and ADP (state 3).  Fluorescence was assessed 
in a microplate reader using KC4 software and corrected for oxygen consumption for the 
corresponding state of respiration.   
 
RNA isolation and mRNA expression analysis-  Total RNA was isolated from cultured 
C2C12 myotubes using TRIzol reagent (Invitrogen) according to manufacturer’s 
instructions.  RNA concentration and quality was assessed using spectrophotometry 
(Ultrospec 2100; Biochrom, UK) and further verified with RNA gels.  The mRNA 
expression of PINK1, Parkin, and BNIP3L/NIX was quantified using StepONE Plus PCR 
System (Applied Biosystems, California, USA) and SYBR
® 
Green Supermix (Quanta 
Biociences, MD, USA).  First-strand c NA synthesis from 2 μg of total RNA was 
performed with primers using Superscript III reverse transcriptase and Oligo(dt)20 
(Invitrogen) according to manufacturer’s instructions.  Forward and reverse primers were 
optimized to verify primer efficiency and dissociation melt curves were analyzed for 
primer specificity.  All samples were run in duplicate, simultaneously with negative 
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controls that contained no cDNA.  Final primers were as follows: LC3b ( OR: 5’-
GCTTGCAGCTCAATGCTAAC-3’, REV: 5’-CCTGCGAGGCATAAACCATGT-3’), 
PINK1 (FOR: 5’-GCTTGCCAATCCCTTCTATG-3’, REV: 5’-
CTCTCGCTGGAGCAGTGAC-3’), Parkin ( OR: 5’-
TGTGACCTGGAACAACAGAGTA-3’, REV: 5’-TCAGGTCCACTCGTGTCAA-3’), 
Bnip3L  ( OR: 5’-TGAGTGACAGACAGGAAACAGA-3’, REV: 5’-
GGCCTGAAACATTCCTTACAA-3’), GAPDH ( OR:  5’- 
AACACTGAGCATCTCCCTCA-3’, REV: 5’-GTGGGTGCAGCGAACTTTAT-3’)  and 
β2-microglogulin ( OR: 5’-GCCAAACCCTCTGTACTTCTCA,  REV: 5’-
TTGGGCACAGTGACAGACTT-3’)  
 Transcript levels were normalized to two housekeeping genes, GAP H and β2-
microglobulin, and analyzed using the 2^-ΔΔCt method.  Statistical significance was 
calculated on Δct values using two-way ANOVA and Boneferroni’s post hoc tests.   
 
Fluorescence microscopy-  C2C12 cells were plated on glass-bottom 6 well dishes (3.5 
mm wells) coated with 0.1% gelatin.  When cells reached a confluency of ~80%, they 
were co-transfected with pBABE GFP-LC3 (Addgene; (23) encoding LC3, which is 
localized to autophagosome membranes after processing, and pDsRed2-Mito (Clontech, 
CA, USA),  an expression vector that encodes a fusion of red fluorescence protein and 
the mitochondrial targeting sequence from COX subunit VIII, using Lipofectamine 2000 
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(Life Technologies, CA, USA).  Fluorescence was visualized using an inverted Nikon 
Eclipse TE2000-U fluorescent microscope equipped with 100x oil objective lens, with a 
custom designed chamber designed to maintain a constant temperature of 37
o
C with 5% 
CO2.  All images were taken at the same exposure and representative images reflect a 
minimum of 30 images per condition, as well as repeated experiments.  
 
Cytochrome c oxidase (COX) activity assay-  Cells were harvested 21 h after the last 
stimulation period and measurement of COX activity was performed as previously 
described (52).  Briefly, cells were resuspended in 120 μl of enzyme extraction buffer 
(100 mM Na-K-phosphate, 2 mM EDTA, pH 7.2), sonicated 3 × 3 sec on ice, and 
subjected to repeated freeze-thaw cycles in liquid N2.  The supernatant fraction 
containing the enzyme extracts was removed and used to measure COX enzyme activity.  
COX activity was measured over time as a reduction in absorbance at 550 nm of reduced 
equine cytochrome c, and activity was quantified using a 96-well plate in a microplate 
reader (Bio-Tek Synergy HT, Winooski, VT) at 30°C.  The data were compiled using 
KC4 software and corrected for protein concentration to determine COX activity. 
 
Immunoblotting and Protein Extraction-  Cultured myotubes were washed 2x with ice-cold PBS 
and scraped in Passive Lysis Buffer (Promega, Madison WI) supplemented with cOmplete 
Protease Inhibitor Cocktail Tablets (Roche, Basel, Switzerland).  Following extractions, protein 
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was quantified using the Bradford method.  Whole cell and mitochondrial fraction extracts (20–
40 μg of protein) were separated using 8-15% SDS-PAGE and then transferred to nitrocellulose 
membranes. Membranes were blocked in 5% skim milk in TBST buffer for 1 h, and then 
incubated overnight at 4°C with primary antibodies directed against COXIV (1:1000; 
Calbiochem), MnSOD (1:000; Upstate Biotechnology), Bnip3L/NIX (1:500; Abcam ab109414), 
LC3B (1:1000; Cell Signaling #2775), p62/SQSTM1 (1:40,0000; Sigma-Aldrich P0067), aciculin 
(1:500; in house), VDAC 1:5000 (Abcam).  Secondary antibodies were used as per 
manufacturer’s suggestions (Santa-Cruz Biotechnologies).  
 
Statistical analysis-  The means and standard errors were calculated for all measured 
values, and statistical significance between groups was determined by ANOVA with 
Boneferroni post-hoc tests (Graphpad, La Jolla, CA).  Results were considered 
statistically significant when P ≤0 05   Graph bars represent the means and   E M  
 
Results 
Mitochondrial dysfunction with autophagy inhibition is ameliorated by chronic 
contractile activity. 
CCA successfully induced mitochondrial biogenesis, resulting in a 1.6-fold increase in 
cytochrome c oxidase (COX) activity (Fig 2A).  This was corroborated by a significant 
2.8-fold increase in cytochrome c oxidase subunit IV (COXIV) protein levels (Figs. 
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2B,2C).  This effect of contractile activity was not observed when autophagy was 
inhibited by BafA.  However, sustained autophagy inhibition invoked the accretion of 
mitochondria that presumably escape degradation as demonstrated by an increase in 
mitochondrial enzyme activity.  Significant elevations of both COX activity and COXIV 
protein were observed with BafA treatment alone (P<0.05).  The combination of BafA 
treatment with CCA did not lead to an additive response in the quantity of mitochondria.   
To assess changes in organelle function, we quantified oxygen consumption in 
isolated mitochondrial fractions across conditions.  As expected state 3 respiration was 3-
4-fold greater than state 4 respiration in mitochondria from control cells.  BafA treatment 
produced mitochondria with severe 2.5-3-fold depressions in both state 4 and state 3 
respiration (Fig 3A).  CCA did not alter the rates of oxygen consumption observed under 
control conditions, but successfully reversed the respiratory dysfunction induced by 
BafA, resulting in a 2-3-fold improvement over the BafA-treated cells, back toward 
control conditions.  Mitochondrial reactive oxygen species (ROS) production was 
elevated in response to autophagic disruption in state 3 (2.3-fold) and state 4 (1.6-fold) 
respiration (Fig 3B).  CCA had no effect on ROS production in control, vehicle-treated 
cells, but ameliorated BafA-induced ROS production and reversed the increase in ROS 
production by 55% to levels that matched untreated controls.  These results indicate that 
CCA can positively regulate mitochondrial function under conditions of cellular stress, 
and attenuate the increase in ROS production resulting from autophagic defects.  The  
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effects of CCA on ROS levels in isolated mitochondria were independent of changes in 
MnSOD, since levels of the protein were unaffected by CCA, but increased by BafA (Fig 
3C,3D). 
 
CCA and autophagy suppression induce mitophagy gene expression. 
In order to explain some of the molecular mechanisms regulating mitophagy during 
contractile-activity, relative changes in gene expression of PINK1, Parkin and 
BNIP3L/NIX were quantified.  CCA led to a 2-fold increase in PINK1 mRNA levels  
(Fig 4), but had no effect on the ubiquitin E3-Ligase Parkin, or the mitophagy targeting 
molecule Bnip3L/NIX.  In contrast, autophagy suppression with BafA led to a large 
increase in PINK1 gene expression, as well as more modest changes in Parkin and 
Bnip3L/NIX (P < 0.05). 
 
In vitro fluorescent characterization of autophagy. 
To further characterize whether CCA potentiates autophagy and mitochondrial clearance, 
we employed live-cell imaging of cells transfected with expression vectors encoding 
GFP-LC3 (23) and DsRed2-Mito.  In vehicle-treated control cells, GFP-LC3 exhibited 
diffuse fluorescence (Fig 5).  Autophagic suppression with BafA considerably 
upregulated the accretion of autophagosomes observed.  CCA appeared to induce a 
greater frequency of LC3-punctae compared to vehicle, control conditions, indicative of 
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autophagy induction.  However, when CCA was coupled to autophagy disruption, LC3 
appeared to be more diffusely redistributed within the cytosol as compared to BafA 
treatment alone.  Co-localization of mitochondria to LC3 did appear to be enhanced in 
the CCA + BafA group, suggestive of enhanced mitophagy.   
 
LC3-II accretion is reduced following contractile-activity with autophagy inhibition. 
We next assessed autophagic flux by examining the levels of autophagy proteins LC3-I 
and LC3-II, as well as the autophagy substrate p62 using immunobloting.  Bafilomycin 
effectively inhibited flux in C2C12 myotubes (Fig 6A-C), as shown by a 24-fold accrual 
in LC3-II protein levels, as well as a 15-fold increase in the LC3-II/LC3-I ratio.  CCA 
had no effect on the very low levels of LC3-II, or on the LC3-II/LC3-I ratio.  However, 
CCA produced a 50% reduction in LC3-II levels (P<0.001) with BafA treatment, with a 
similar significant downregulation in the LC3-II/LC3-I ratio, indicating a reduction in 
LC3-II formation when autophagy was inhibited.  Whole cell p62 levels were also 
significantly enhanced following BafA treatment (Fig 7A,7C), accompanied by a 
dramatic 30-fold increase in p62 levels associated with the isolated mitochondria (Fig 
7B,7D).  CCA tended to reduce p62 levels in whole cell lysates (P=0.06), and 
significantly decreased the localization of p62 to mitochondria, indicating a lower drive 
for mitophagy in the presence of enhanced mitochondrial quality.     
 
  
66 
 
N-Acetyl-L-cysteine treatment  
In view of the fact that CCA attenuated mitochondrial defects and enhanced autophagy 
flux, accompanied by a reversal in ROS production in BafA treated groups, we sought to 
investigate whether these alterations could be mediated by the reduced ROS production.  
Thus, we treated myotubes with N-Acetyl-L-cysteine (NAC), a thiol antioxidant, to 
assess the role of ROS in modulating autophagy flux with BafA treatment.  NAC reduced 
LC3-II levels by 50% in myotubes treated with BafA for 72 hrs (Fig 8A), similar to our 
observations with CCA (Fig 6).  Further NAC attenuated autophagic flux by 2.4-fold (Fig 
8B).  The reductions to LC3-II observed with NAC treatment were independent of 
alterations in p62 (Fig 8A), indicating that antioxidant treatment did not affect protein 
aggregate clearance.  These results indicate ROS are key modulators of cellular 
autophagy flux and directly contribute to autophagy induction in muscle cells.   
 
Discussion 
Autophagy is a critical survival mechanism facilitating protein turnover and pathogen 
defense in post-mitotic cells.  The process was first recognized for its cytoprotective role 
in the re-mobilization of cellular nutrients in response to nutrient duress (50) via 
inhibition of TOR (38).  Failure of autophagy has been linked to congenital muscular 
dystrophies, and the reinstatement of normal autophagy flux has been shown to 
ameliorate the dystrophic phenotype and myofibrillar degeneration (13).  Muscle-specific 
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autophagy knockouts, Atg7
-/-
 mice display a loss of fiber-integrity and muscle mass, and 
the accumulation of abnormal mitochondria (33).  Autophagy disruption has been noted 
in a variety of myopathologies, including sporadic inclusion body myositis (IBM), and 
polymyositis with mitochondrial pathology (PM-mito) (17), characterized by protein 
aggregation and progressive muscle weakness.  Inefficient clearance of toxic protein 
aggregates may facilitate decrements in muscle function with pathology or age.  In 
healthy cells, autophagy is a tightly regulated process, and it has consistently been shown 
to be transiently upregulated in response to exercise in skeletal muscle (14, 20, 28).  This 
is likely because contractile activity induces a host of transcriptional and metabolic 
alterations that may account for an enhanced autophagy drive.  Moreover, the process has 
been suggested to necessitate the adaptation to a more oxidative phenotype in muscle 
(29).   
Mitochondria are both key mediators of cellular bioenergetics and robust initiators 
of cellular apoptotic signaling (58), thus mitochondrial quality control is both integral to 
energy production and cytoprotection (31).  Organelle availability reflects a dynamic 
relationship between catabolism (i.e. mitophagy), and the anabolic process of biogenesis 
in response to enhanced metabolic demands.  Chronic contractile activity (CCA) has been 
established as an effective model of mitochondrial biogenesis (52), which activates a 
transcriptional profile resembling the response to chronic treadmill training in mice (3).  
Muscle contraction results in bursts of ROS (16), as well as 5’AMP-activated kinase 
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(AMPK) activation, and can mediate the cross-talk between exercise and autophagy 
through a convergence on mTOR signaling.  Downstream AMPK phosphorylation targets 
include the autophagy-initiator kinase ULK1 (34), along with PGC-1α which positively 
regulates TFEB (51), a transcription factor important for lysosomal biogenesis.  
However, the mechanism by which exercise modulates selective autophagy are far from 
clear cut, and the effects of autophagy suppression on mitochondrial function and content 
have yet to be investigated.  Thus, the purpose of our study was to examine the role of 
autophagy in the mitochondrial adaptations to contractile activity, and the implications of 
autophagy suppression on mitochondrial quality, function and content in muscle cells.   
Our expectation was that a block in autophagy would inhibit mitochondrial turnover via 
impaired mitophagy, leading to the accumulation of aberrant organelles, and that CCA 
would counterbalance mitochondrial dysfunction by providing nascent, functional 
organelles. 
To evaluate the effects of autophagy inhibition on the molecular adaptations to 
chronic contractile activity (CCA), we treated differentiated C2C12 myotubes with a 
specific inhibitor of the lysosomal V-ATPase Bafilomycin A1 (BafA) for the duration of 
the CCA protocol to monitor the effects of sustained autophagy deficit on the function 
and quality of the mitochondria, in order to model the prolonged defects characteristic of 
pathological states.  As previously reported (5, 52), CCA effectively increased 
mitochondrial content as observed by approximately 2-fold increases in COXIV protein 
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expression and COX activity.  In the absence of CCA, BafA led to severe deficits to 
mitochondrial respiration.  This effect was completely reversed following CCA, 
indicating that contractile activity led to the production of nascent, functional organelles.  
This evidence also establishes selective autophagy as an integral mechanism which 
maintains organelle fitness and function.  We demonstrate that contractile activity can 
rescue the oxidative respiration insult induced by defective mitochondrial turnover.  BafA 
treatment also upregulated the mitophagy-specific genes PINK1, Parkin and BNIP3L, 
suggesting that defective organelle clearance induces the expression of genes responsible 
for mitophagy signaling.  CCA alone resulted in enhanced PINK1 expression, indicating 
a heightened reliance on mitochondrial quality-control pathways during contractile 
activity-induced mitochondrial biogenesis.  These findings are in agreement with our 
recent work which demonstrated a greater mitophagy drive post-exercise in skeletal 
muscle (46).   
Reactive oxygen species are a normal by-product of oxidative phosphorylation, 
escaping complexes I and III in the process of oxidative phosphorylation.  Mitochondrial 
matrix antioxidants such as manganese superoxide dismutase (MnSOD) efficiently 
quench superoxide anion radicals, however with mitochondrial dysfunction, free-radicals 
out-live internal defense systems and this exacerbates the production of intracellular 
ROS.  Excessive ROS levels are known to trigger apoptotic signaling and potentiate 
muscle wasting stimuli (2).  Our results indicate ROS were upregulated with autophagic 
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inhibition, despite the marked elevation in MnSOD protein with BafA treatment.  CCA 
reversed this increase in ROS production, thereby restoring levels back toward control 
values.   Interestingly, our data reveal that CCA overturned the dysfunctional phenotype 
induced by aberrant organelle elimination. 
To investigate the effects of CCA on autophagy flux, we assessed LC3-II/LC3-I 
protein levels in the presence of autophagy inhibition.  BafA drastically disrupted 
autophagic flux, resulting in a 25-fold increase in LC3-II accretion.  Although CCA alone 
resulted in an increase in the population of cells with observable GFP-LC3 fluorescent 
punctae, we did not observe a significant increase in LC3-II protein, or in the ratio of 
LC3-II/LC3-I.  Indeed, the decrease in LC3-II/LC3- ratio with CCA likely indicates a 
reduced mitophagic requirement, given the higher quality of mitochondria produced with 
CCA.  Consistent with this is the modest reduction in mitochondrial-associated p62 with 
CCA.  A similar phenomenon was recently illustrated by Jiang and colleagues, who 
found a reduction of flux with exercise following chloroquine treatment (21).  The 
alternate explanation is that CCA enhanced cargo clearance via an increase in lysosomal 
capacity.  This possibility remains to be explored.   
We postulated that the observed CCA-associated decrement in ROS could 
mediate the ability of CCA to re-establish autophagic flux with BafA treatment.  To 
examine this possibility, we co-treated differentiated myotubes with the non-specific 
antioxidant NAC, along with BafA.  Our results indicate that NAC reduced LC3-II 
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accretion in BafA treated cells to an equivalent extent as CCA, by about 50%.  The 
ability of NAC to reduce autophagosome accretion in this model of autophagy 
suppression suggests that CCA modulates ROS production to restore autophagy flux.  
Thus, we speculate that in models of suppressed autophagy, approximately 50% of 
autophagy flux can be attributed to disruptions in cellular redox status. 
In conclusion, our results indicate that CCA mediates a reversal of mitochondrial 
deficits induced by aberrant autophagy.  Thus, contractile activity represents a potential 
therapeutic intervention against mitochondrial dysfunction in muscle, since it stimulates 
the production of healthier mitochondria, and therefore normalizes mitophagy flux.  
These results support the view that mitophagy mediates an indispensable mitochondrial 
quality control pathway in muscle cells, and that contractile activity can reverse 
mitophagy defects and contribute to muscle health. 
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Figure 2:   A-induced mitochondrial biogenesis    ifferentiated 
myotubes were chronically stimulated to induce mitochondrial 
biogenesis in the presence of vehicle or  afilomycin A1 ( afA)  A: 
 ytochrome oxidase ( OX) activity (*P < 0 05, vs  vehicle  on; †P < 
0 05, Main effect of  afA vs  vehicle; n=6) B: Representative western-
blot of whole cell extracts probed for  OXIV and aciculin protein  C: 
Graphical densitometric quantification,  OXIV normalized to 
aciculin  (*P < 0 001 vs  vehicle  on; n = 8)  A U  arbitrary units  
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A 
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Figure 3:  Mitochondrial respiration and RO  production   Mitochondria were isolated 
from myotube tissue culture by differential centrifugation    tate 4 and state 3 respiration 
were measured and normalized to protein concentration  RO  production was determined 
on isolated mitochondria and normalized to respiration  A:  tate 4 and state 3 respiration 
(*P < 0 05, vs   on  tate 4; †P < 0 001, vs   on  tate 3; ‡P < 0 05, afA+  A vs  afA 
 on;  n = 4)  B: Mitochondrial RO  production (*P < 0 05, vs   on  tate 4; †P < 0 001, 
vs   on  tate 3; ‡P < 0 05, afA+  A vs   afA  on;  n = 4)  C: Representative western 
blot of Mn O  protein expression  D: Graphical quantification († P < 0 001, Main effect 
of  afA vs  vehicle; n = 6)   A U  arbitrary units  
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Figure 4: Real-time P R analysis of mitophagy mRNA expression 
in control and   A myotubes, treated with vehicle (Veh) or 
 afilomycin A1 ( afA)   Transcript levels were normalized to both 
β-actin and GAP H (*P < 0 05, vs  control levels of the same 
transcript)   
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Figure 5: Live-cell fluorescence microscopy of  2 12 myotubes co-expressing G P-
L 3 and mito  red at 100x magnification   ully differentiated myotubes were 
chronically stimulated to induce mitochondrial biogenesis in the presence of vehicle 
or  afilomycin A1   
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Figure 6:  Expression of autophagy proteins in response to   A in  2 12 
myotubes, treated with  afilomycin A1 ( afA)  A: Representative western-
blot  B: Graphical densitometric quantification; L 3-II normalized to α-
tubulin protein (*P < 0 001,  afA   A vs   afA  on;  †P < 0 001, Main 
effect of  afA vs  vehicle n = 8)  C: L 3-II normalized to L 3-I protein 
(*P < 0 001,  afA   A vs   afA  on;  †P < 0 001, Main effect of  afA vs  
vehicle n = 8)  A U  arbitrary units  
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Figure 7:  Expression of autophagy proteins in response to   A in  2 12 
myotubes treated with  afilomycin A1 (BafA)  Representative western-blots; A: 
Whole cell extracts and B: mitochondrial fractions were probed for p62, V A  
and α-tubulin   Graphical densitometric quantification C: Total p62 normalized to 
α-tubulin (†P < 0 01, Main effect of BafA vs  vehicle; P=0 06 vehicle   A vs  
vehicle  on; n = 5)  D:  Mitochondrial p62 (†P < 0 001, Main effect of BafA vs  
vehicle; *P < 0 01,  afA on vs  afA +  A; n = 3)  A U  arbitrary units  
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Future Work 
1. We document that autophagy is an integral process mediating mitochondrial 
homeostasis in muscle cells.  Future work could involve in-depth assessment of the 
response of mitophagy to exercise, and the response of lysosomal biogenesis and 
enzymes in response to CCA.  Further, we could apply a combination of genetic and 
pharmacological interventions of inducing and inhibiting autophagy to assess the role of 
this process in regulating muscle mass and mitochondrial content in models of use, disuse 
and pathology. 
 
2. Since PINK1 mRNA levels were found to be upregulated in response to contractile 
activity in muscle cells, to further elucidate the role of PINK1 in contractile activity we 
could use siRNA-mediated knockdown and visualize mitochondrial dynamics in 
myoblasts and myotubes to assess the role of the kinase in muscle mitochondria.   
Further, we could knockdown key autophagy proteins such as ULK1 or ATG7 in muscle 
cells in culture as a genetic approach to autophagy suppression, in order to gauge the 
implications for muscle homeostasis.   Inflammatory cytokines (TNF-α, IL-6, IL-1) could 
be used as indices of muscle health, and can be measured in response to autophagy 
protein abrogation in conjunction with indices of mitochondrial health.   The same 
chronic contractile activity protocol (3h x 4d) could be utilized to assess the effects of 
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such knockdown on the mitochondrial adaptations to contractile activity.  TUNEL assays 
may be performed to measure the implications of mitophagy on whole cell viability, and 
apoptotic markers such as cytosolic AIF and cytochrome c, could be all measured in 
response to CCA in order to determine if contractile activity could mediate a 
cytoprotective response. 
Conversely, cells could be treated with autophagy inducing agents such as mTOR-
dependent Rapamycin, or mTOR-independent inducers such as Clonadine and Trehalose 
and mitochondrial markers and adaptations could be assessed in response to CCA.  
Mitochondrial turnover could be visually assessed (fluorescence microscopy) in response 
to CCA in vitro using DsRed1-E5/Mito-timer, a fluorescent probe that gradually 
transitions from red to green over time and allows for ratio-metric calculations to 
examine organelle turnover.  This will provide novel insights on the influence of 
contractile activity on rates of mitochondrial turnover.   
2.  To further elucidate the role of autophagy in skeletal muscle and mitochondrial 
quality, we could confirm our present findings in animal models.  Autophagy-activators 
could be administered to mouse models undergoing models of use (exercise) and disuse 
(denervation) to monitor whether there is any effect on skeletal muscle mass (attenuation 
or preservation) in response to elevated autophagy.  PINK1 immunohistochemistry can 
be performed on muscle-cross-sections to determine the localization and prevalence of 
  
88 
 
the protein in muscle.  Immunohistochemistry of muscle cross-sections during conditions 
of use and disuse can be similarly assessed for several mitochondrial targeted proteins, 
such as BNIP3L, Parkin, Trap1 and the mitochondrial anti-apototic protein Bcl-2. 
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Appendix A: Data and Statistical Analyses 
Table 2A. Individual values and Statistical analysis for COX Activity Assay 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 1.382 1.794 2.738 2.792 
2 1.267 1.768 2.494 3.425 
3 0.845 1.179 1.663 2.283 
4 1.223 2.013 2.342 1.347 
5 1.228 1.873 2.355 3.061 
6 1.187 2.61 2.366 2.707 
Average 1.188 1.872 2.326 2.602 
Std. Dev 0.165 0.420 0.326 0.659 
Std. Error 0.074 0.188 0.146 0.295 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ns No   
CCA ** Yes   
Drug *** Yes   
     
     
Bonferroni post tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle 0.735 2.749 P < 0.05 * 
Bafilomycin A1 0.385 1.44 P > 0.05 ns 
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Table 2B. Individual values and Statistical analysis for COXIV protein 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 0.476 1.650 0.506 1.047 
2 0.502 1.176 0.845 1.000 
3 0.459 1.231 0.310 0.582 
4 0.405 1.364 0.716 0.918 
5 0.400 0.660 0.645 1.040 
6 0.385 1.304 0.415 0.869 
7 0.587 1.295 0.906 0.726 
8 0.131 1.200 1.291  
Average 0.437 1.230 0.572 0.909 
Std. Dev 0.125 0.257 0.296 0.161 
Std. Error 0.019 0.132 0.081 0.071 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction *** Yes   
CCA *** Yes   
Drug ns No   
     
     
Bonferroni post tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle 0.816 6.869 P<0.001 *** 
Bafilomycin A1 0.179 1.454 P > 0.05 ns 
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Table 3Ai. Individual values and Statistical analysis for State 4 Respiration 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 4.730 5.220 1.590 4.610 
2 3.950 3.620 1.820 5.760 
3 6.650 4.580 1.810 2.260 
4 2.551 3.811 1.614 2.386 
Average 4.470 4.308 1.708 3.754 
Std. Dev 1.481 0.638 0.107 1.488 
Std. Error 0.855 0.368 0.062 0.859 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ns No   
CCA ns No   
Drug * Yes   
     
     
Bonferroni post tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle -0.163 0.181 P > 0.05 ns 
Bafilomycin A1 2.046 2.281 P > 0.05 ns 
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Table 3A ii. Individual values and Statistical analysis for State 3 Respiration 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 16.810 18.520 3.900 13.180 
2 14.480 14.770 5.730 9.080 
3 11.540 10.890 4.300 6.960 
4 13.399 16.476 5.328 9.743 
Average 14.057 15.164 4.814 9.741 
Std. Dev 1.906 2.802 0.742 2.236 
Std. Error 1.100 1.618 0.428 1.291 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ns No   
CCA * Yes   
Drug *** Yes   
     
     
Bonferroni post tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle 1.107 0.657 P > 0.05 ns 
Bafilomycin A1 4.926 2.924 P < 0.05 * 
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Table 3B i. Individual values and Statistical analysis for State 4 ROS 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 1844.54 4239.62 6847.00 2047.15 
2 3689.90 5113.48 5266.83 1674.78 
3 1838.43 2583.27 5794.59 4362.09 
4 4372.54 2920.55 6855.11 4576.16 
Average 2936.35 3714.23 6190.88 3165.05 
Std. Dev 1121.16 1017.71 686.04 1312.89 
Std. Error 647.30 587.57 396.09 758.00 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ** Yes   
CCA ns No   
Drug * Yes   
     
     
Bonferroni post tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle 777.9 0.900 P > 0.05 ns 
Bafilomycin A1 -3026 3.499 P<0.01 ** 
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Table 3B ii. Individual values and Statistical analysis for State 3 ROS 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 452.462 1015.000 3013.154 735.308 
2 793.774 974.416 1229.512 696.645 
3 883.530 1011.370 2283.880 1320.810 
4 821.795 636.270 1872.770 1042.050 
Average 737.890 909.264 2099.829 948.703 
Std. Dev 167.961 158.411 647.504 253.105 
Std. Error 96.972 91.459 373.837 146.130 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ** Yes   
CCA * Yes   
Drug ** Yes   
     
     
Bonferroni post tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle 171.4 0.573 P > 0.05 ns 
Bafilomycin A1 -1151 3.849 P<0.01 ** 
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Table 3D. Individual values and Statistical analysis for MnSOD protein 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 0.602 0.624 1.679 1.240 
2 0.805 0.362 2.079 1.137 
3 0.105 0.714 0.390 1.495 
4 0.397 0.528 1.337 1.188 
5 0.656 0.691 1.647 1.134 
6 0.505 1.043 2.293 2.078 
7 0.683 0.601  0.834 
Average 0.512 0.660 1.571 1.379 
Std. Dev 0.213 0.193 0.612 0.366 
Std. Error 0.099 0.093 0.274 0.150 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ns No   
CCA ns No   
Drug *** Yes   
     
     
Bonferroni post-tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle 0.1157 0.536 P > 0.05 ns 
Bafilomycin A1 -0.2701 1.201 P > 0.05 ns 
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Table 4A i. Individual values and Statistical analysis for PINK1 mRNA normalized to 2 
house keeping genes.  
 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 105.702 136.751 202.248 250.936 
2 95.022 197.010 275.584 325.643 
3 100.380 106.235 265.523 202.215 
4 88.802 142.303 154.598 128.969 
5 91.507 228.270 222.378 291.564 
6 116.528 218.342 307.040 103.588 
7 81.841 254.281 451.888 440.725 
8 101.039 161.530 250.683 210.388 
9 87.905 206.753 284.408 343.610 
10 90.581 154.297 203.386 187.575 
Average 99.657 171.485 237.895 217.152 
Std. Dev 9.701 44.866 77.163 98.639 
Std. Error 4.193 20.320 22.668 36.215 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction * Yes   
CCA ns No   
Drug *** Yes   
     
     
Bonferroni post-tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle 84.65 2.704 P < 0.05 * 
Bafilomycin A1 -13.25 0.423 P > 0.05 ns 
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Table 4A ii. Individual values and Statistical analysis for Parkin mRNA normalized to 2 
house keeping genes.  
 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 11.021 9.603 21.533 17.735 
2 11.045 15.004 38.184 34.705 
3 12.504 5.892 27.176 17.753 
4 12.159 20.789 21.516 8.673 
5 11.325 9.213 17.039 9.640 
6 10.687 7.848 21.442 14.283 
7 9.264 1.806 6.246 4.598 
8 9.225 2.109 4.753 2.687 
9 9.016 5.152 6.967 12.816 
10 11.168 12.061 15.480 6.525 
Average 11.457 11.391 24.482 17.131 
Std. Dev 1.172 5.615 10.044 8.846 
Std. Error 0.292 2.252 3.039 3.853 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ns No   
CCA ns No   
Drug * Yes   
     
     
Bonferroni post-tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle -1.794 0.530 P > 0.05 ns 
Bafilomycin A1 -5.092 1.505 P > 0.05 ns 
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Table 4A iii. Individual values and Statistical analysis for Bnip3L mRNA normalized to 
2 house keeping genes.  
 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 318.540 559.680 515.070 695.031 
2 336.193 370.173 443.701 624.447 
3 347.229 334.286 500.443 509.594 
4 394.969 366.214 463.230 398.808 
5 348.628 460.699 506.872 648.878 
6 304.579 467.252 642.918 532.337 
7 239.452 196.273 461.043 423.882 
8 333.742 197.555 373.908 333.776 
9 348.429 397.631 511.082 487.193 
10 375.320 249.804 347.029 368.682 
Average 341.689 426.384 512.039 568.182 
Std. Dev 40.137 115.362 78.612 119.079 
Std. Error 12.729 34.582 28.491 44.412 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ns No   
CCA ns No   
Drug *** Yes   
     
     
Bonferroni post-tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle 25.25 0.578 P > 0.05 ns 
Bafilomycin A1 25.73 0.589 P > 0.05 ns 
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Table 6B. Individual values and Statistical analysis for LC3-II protein 
 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 0.021 0.024 1.000 0.571 
2 0.030 0.039 1.761 0.517 
3 0.084 0.038 1.395 0.436 
4 0.023 0.027 1.390 0.707 
5 0.088 0.056 1.000 0.566 
6 0.024 0.145 1.000 0.686 
7 0.080 0.118 1.092 0.637 
8 0.050 0.122 1.100 0.535 
Average 0.045 0.055 1.258 0.580 
Std. Dev 0.028 0.046 0.257 0.085 
Std. Error 0.013 0.019 0.128 0.042 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction *** Yes   
CCA *** Yes   
Drug *** Yes   
     
     
Bonferroni post-tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle 0.021 0.288 P > 0.05 ns 
Bafilomycin A1 -0.635 8.619 P<0.001 *** 
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Table 6C. Individual values and Statistical analysis for LC3-II:LC3I protein ratio 
 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 0.023 0.029 1.000 0.976 
2 0.154 0.248 1.632 0.472 
3 0.159 0.276 1.650 0.502 
4 0.061 0.180 1.423 0.486 
5 0.092 0.055 1.042 0.382 
6 0.030 0.125 1.000 0.863 
7 0.231 0.168 1.560 0.653 
8 0.318 0.505 3.119 0.969 
Average 0.086 0.152 1.291 0.614 
Std. Dev 0.098 0.142 0.654 0.225 
Std. Error 0.024 0.041 0.128 0.099 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ** Yes   
CCA ** Yes   
Drug *** Yes   
     
     
Bonferroni post-tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle 0.064 0.343 P > 0.05 ns 
Bafilomycin A1 -0.890 4.714 P<0.001 *** 
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Table 7C. Individual values and Statistical analysis for whole cell p62 protein 
 
     
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 0.929 0.648 0.959 1.470 
2 1.185 0.674 2.011 1.401 
3 0.702 0.613 1.639 0.811 
4 1.093 0.597 1.482 1.302 
5 0.615 1.061 2.637 1.593 
6 1.892 0.477 0.817 0.941 
Average 1.069 0.678 1.591 1.253 
Std. Dev 0.419 0.182 0.617 0.283 
Std. Error 0.187 0.081 0.276 0.126 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ns p<0.06   
CCA ns No   
Drug ** Yes   
     
     
Bonferroni post-tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle -0.391 1.512 P > 0.05 ns 
Bafilomycin A1 -0.338 1.307 P > 0.05 ns 
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Table 7D. Individual values and Statistical analysis for mitochondrial-associated p62 
protein 
 
N Vehicle  3 nM BafA  
 Control CCA Control CCA 
1 0.037 0.038 0.949 0.847 
2 0.024 0.023 0.991 0.839 
3 0.035 0.026 0.943 0.909 
Average 0.032 0.029 0.961 0.865 
Std. Dev 0.006 0.007 0.021 0.031 
Std. Error 0.004 0.005 0.015 0.022 
     
     
Two Way ANOVA- Control vs. CCA   
Source of 
Variation 
P value 
summary 
Significant?   
Interaction ** Yes   
CCA ** Yes   
Drug *** Yes   
     
     
Bonferroni post-tests- Control vs. CCA   
Treatment Difference t P Value Summary 
Vehicle -0.003 0.146 P > 0.05 ns 
Bafilomycin A1 -0.096 4.946 P<0.01 ** 
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Table 8B. Individual values and Statistical analysis for NAC + BafA treated myotubes 
 
N 24 
Hours 
   72 
Hours 
  
 Vehicle NAC BafA BafA + 
NAC 
Vehicle BafA BafA + 
NAC 
1 0.229 0.034 0.812 0.488 0.243 1.200 0.604 
2 0.187 0.010 0.410 0.443 0.161 1.479 0.630 
3 0.048 0.010 1.250 0.203 0.091 1.072 0.618 
Average 0.155 0.018 0.824 0.378 0.165 1.251 0.617 
Std. Dev 0.077 0.012 0.343 0.125 0.062 0.170 0.010 
Std. 
Error 
0.055 0.008 0.243 0.088 0.044 0.120 0.007 
 
Bonferroni's Multiple 
Comparison Test 
Mean Diff. t P value 95% CI of diff 
  Vehicle vs BafA -0.669 4.267 P < 0.05 -1.250 to -
0.089 
  Vehicle vs BafA -1.096 6.986 P < 0.001 -1.676 to -
0.515 
  NAC vs BafA -0.806 5.138 P < 0.01 -1.386 to -
0.225 
  NAC vs BafA -1.232 7.857 P < 0.001 -1.813 to -
0.652 
  NAC vs BafA + NAC -0.599 3.820 P < 0.05 -1.179 to -
0.018 
  BafA vs Vehicle 0.659 4.201 P < 0.05 0.078 to 1.239 
  BafA + NAC vs BafA -0.872 5.561 P < 0.01 -1.452 to -
0.292 
  Vehicle vs BafA -1.085 6.920 P < 0.001 -1.666 to -
0.505 
  BafA vs BafA + NAC 0.633 4.038 P < 0.05 0.053 to 1.214 
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Table 8B. contd.      
Autophagy Flux LC3II     
Two Way ANOVA-      
Source of Variation P value 
summary 
Significant?   
Interaction ns No   
Drug ** Yes   
Time  ns No   
     
     
Bonferroni post-tests- Control vs. CCA    
Treatment Difference t P Value Summary 
24h -0.445 2.003 P > 0.05 ns 
72h -0.633 2.847 P < 0.05 * 
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Appendix B: Additional Data 
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Supp. Figure 1: Real-time P R analysis of  L 3 
mRNA expression in control and   A myotubes, 
treated with vehicle (Veh) or  afilomycin A1 
( afA)   Transcript levels were normalized to both 
β-actin and GAP H  
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Supp. Figure 2: Mitochondrial morphology with autophagy 
suppression  Live-cell fluorescent mitochondrial visualization in 
 2 12 myotubes transfected with mito  red at 100x 
magnification in the presence of vehicle or  afilomycin A1  
BafA 3 nM 
Vehicle    
DsRed2-Mito 
 DsRed2-Mito 
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        -         +           -          +  
 on    A 
Rab5 
Beclin1 
ULK1 
ATG7 
GAPDH 
BafA 
Supp. Figure 3: Representative 
western-blot of whole cell extracts 
probed for ATG7,  eclin1, ULK1, 
Rab5 and GAP H protein   
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Appendix C: Laboratory Methods and Protocols 
Cell Culture 
 
Cells 
 
1. C2C12 murine skeletal muscle cells (ATCC, CRL-1772) 
 
Materials 
 
1.  ulbecco’s Modified Eagle’s Medium ( MEM;  igma  -5796/500ml) 
2. Fetal Bovine Serum (FBS; Fisher Scientifitc SH3039603C/500ml) 
a. Aliquoted into 50ml sterile conical tubes and stored at -20°C 
3. Penicillin/Streptomycin (P/S; Invitrogen 15140-122/100ml) 
a. Sterile aliquots of 6mls and stored at -20°C) 
4. Horse Serum (HS; Invitrogen 16050-114/1000ml) 
a. Aliquoted into 50ml sterile conical tubes and stored at -20°C 
b. Heat-inactivated for 30 minutes at 56.0°C 
5.  0.25% Trypsin-EDTA (1x), phenol red (Invitrogen 25200-072/500ml) 
a. Sterile aliquots of 30mls stored at -20°C 
6.  ulbecco’s Phosphate  uffered  aline (P  ;  igma  -8537/500ml) 
7. 15ml conical tubes, sterile (BD Falcon 352097) 
8. 50ml conical tubes, sterile (BD Falcon 352098) 
9. 175cm2 canted/vented tissue cultured flasks (BD Falcon 353112) 
10. 6-well sterile tissue culture dish (Sarstedt 83.1839.300) 
11. Gelatin (Sigma G1890) 
a. 0.1% solution autoclaved for sterilization 
 
Procedure 
 
1. Allow myoblasts to proliferate in 175cm2 flask with growth medium (GM; 
DMEM supplemented with 10% FBS and 1% P/S) until 70% confluent. 
2. Prepare six 6-well dishes for plating by coating the bottom surface with 0.1% 
gelatin and allow to fully dry in laminar flow hood.  
3. Pre-heat GM, trypsin and PBS in 37°C water bath for 30 minutes prior to use. 
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4. Discard old GM from tissue culture flask and wash with 10mL of PBS to rinse off 
remaining GM.  
5. Apply 5mL of trypsin in the flask and place in the incubator at 37°C for 3 
minutes. 
6. Remove flask from incubator and gently knock sides of the flask to ensure cells 
are lifted from flask bottom. Remove trypsin with cells and place into a sterile 
15mL conical tube.  
7. Rinse flask with 5mls GM and add to sterile 15mL conical tube containing the 
cells. 
8. Spin tube for 3 minutes at 1400rpm at room temperature. 
9. Discard the supernatant and add 1mL of GM for resuspension with 1ml pipette.  
10. Add 3mL of GM to resuspended cell mixture for a total volume of 4mL.  
11. Fill each well of tissue culture dishes with 2mls of GM and add 100µl of cell 
mixture to each well.  
12. Rotate plate in a circular motion for 30 sec and subsequently place into 37°C 
incubator overnight. 
13. The following day remove GM from cells and replace with differentiation 
medium (DM; DMEM supplemented with 5% heat-inactivated HS and 1% P/S) 
once myoblasts are 90-95% confluent. 
14. Refresh DM every other day. Mature myotubes will form after five days and be 
ready for contractile activity.  
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Cell Harvesting From Plates for Enzyme Assays 
 
1. Grow cells up in two 10 cm dishes. 
2. Pour off the medium. Wash each plate twice with 5 ml cold Dulbecco’s Phosphate 
Buffered Saline (DPBS;  Sigma D-5527) without EDTA. Discard and keep the 
plates on ice during the entire procedure. Remove all of the DPBS the second time 
to avoid excessive volume at the end. 
3. Add 0.8 ml of cold DPBS to plate A. Scrape with rubber policeman and transfer to 
plate B. Scrape and add to a pre-labelled eppendorf tube with a hole on the top. 
4. Spin the cells at 4 oC for 3 min at 13.0 rpm in a microcentrifuge. Discard the 
supernate with a Pasteur pipette. 
5. Add 100 μl enzyme extraction buffer and vortex vigorously to disperse the pellet  
6. Sonicate 3 x 3  sec on ice, make sure that the sonicator is set to 30. 
7. Freeze in liq N2 and thaw 5 min at 37 
o
C. Vortex vigorously for 5 sec. 
8. Spin in microcentrifuge at 4 oC for 5 min at 13.0 rpm. 
9. Remove the supernate and add it to a new labelled eppendorf tube with a hole on 
the top. 
10. Add 100 μl enzyme extraction buffer to the pellet and vortex vigorously  
11. Repeat steps 5 to 7.  For the last spin in the microcentrifuge spin the samples for 5 
minutes at 13.0 rpm. 
12. Combine the supernates and use immediately for enzyme assays, or freeze in liq N2. 
13. Measure the total protein concentration using Bradford protein assays. 
14.  et aside 40μl to measure the total protein concentration using Bradford protein 
assays. 
15. Set up plate reader according to the protocol for COX Assay for the microplate 
reader. 
16. Your sample should add up to 50 μl    or  2 12 cells take 40 μl of extraction 
buffer and add to the bottom of three wells   Then add 10 μl of the sample to each 
well and mix by shaking the bottom of the plate.   
17. Use the multipipette to add 250 μl of test solution to the wells and quickly place 
the plate onto the tray of the plate reader to measure rates of oxidation.   
18. For differentiated C2C12 cells you can dilute your samples by half with extraction 
buffer    or example, 25 μl of sample plus  25 μl of extraction buffer   Then take 
10 μl of your sample to do your  OX assay and use the remainder to measure 
protein concentration.   
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Chronic Contractile Activity of C2C12 Myotubes in Culture 
 
Stimulation of muscle cells to induce CCA: Lids from plastic six-well dishes (3.5-mm 
wells) were fitted with two platinum wire electrodes such that 2-cm lengths ran parallel to 
each other at opposite ends of the dish 2 cm apart. Myotubes were subjected to electrical 
stimulation-induced contractile activity in a parallel circuit (4 six-well dishes at a 
time/protocol) at a frequency of 5 Hz and an intensity of 9 V chronically for 3 h/day over 
4 successive days beginning on day 4  of differentiation, as described previously (7, 17, 
18).  Differentiation medium (3 ml) was replenished 1 h prior to stimulation. Following 
this time, custom-made lids with implanted electrodes replaced typical lids, and dishes 
were attached to the electrical stimulator unit. Each well was carefully inspected to 
ensure electrodes were submerged in the medium prior to the stimulation. Myotubes were 
quiescent for 21 h after each bout of contractile activity, and the medium was changed 1h 
prior to stimulation each day. The total stimulation protocol lasts for 4 days, and cells 
were collected for enzyme, protein, or RNA extractions 21 h after the fourth stimulation 
period. We define this treatment CCA in this cell culture model to differentiate it from 
the responses observed under more acute stimulation conditions. 
 
Cells 
1. C2C12 murine myocytes (ATCC) 
 
Materials 
1. Electrical Stimulator  
 Gange bipolar output (+ /- amplitude adjustable using one knob) 
 Output voltage range = 0 to +/- 30V 
 Maximum Output current = 1A 
 Adjustable output pulse duration from 0.001 to 0.1 seconds (10-1 kHz) 
 Adjustable output pulse repetition from 0.0005 to 0.01 seconds (100-2 kHz) 
 Adjustable polarity duration range from 1 to 100 seconds (0.01 to 1 Hz) 
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Polarity duration range = time duration for the output “pulse burst” to be positive 
before switching to a similar negative (amplitude) pulse burst.  Positive and 
negative duration are of equal value except for the amplitude. 
 
2. 6-well sterile plastic culture dishes with modified covers for electrical stimulation 
(see below).  Coat 6-well plates with 0.1% gelatin and leave to dry in the hood. 
 
Procedures 
 
1:  Differentiate C2C12 Myotubes, preferably cells under 15 passages as described in 
the Differentiation of C2C12 cells protocol. 
2:  Replace media with (15mL for 10 -cm plates; 3 ml for 3.5-mm well) of fresh DM 
1 hour prior to onset of stimulation. Mark condition on side of bottom plate. 
3:  Spray stimulator lids with ethanol and place under UV light until dry. 
4:  Replace lids with custom fitted wire electrode lids and attached probes making 
sure that each wire is fully immersed in media and lids sit flat on dishes and allow 
cells to equilibrate for 10 min. 
5: Turn on stimulator unit to 9 V and a frequency of 5 Hz, continue stimulating for 3 
hrs. 
6:  Once the 3 h of stimulation is complete, replace lids and media for fresh DM. 
7:  Wash stimulator lids with warm water, using a gentle-gloved hand to remove 
residue from platinum wire, perform a final rinse with dH2O and spray with 
ethanol before storing for the next session. 
 
-----Repeat previous steps for 4 days------ 
8:  After a 21 hour recovery period, harvest the cells for the various assays.   
 
 
Before each stimulation protocol, electrodes are rinsed with ddH2O, sprayed and 
wiped with 70% ethanol and UV light sterilized for a minimum of 20 min. 
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2. Myotubes (80-90% confluence) are stimulated in a parallel circuit (up to 3 6-well 
dishes at a time/protocol) at 5Hz, 12V for the acute stimulation protocol and at 
5Hz, 10V for the chronic or continuous stimulation protocols.  
 
 
 
 
 
 
 
Electrical Stimulation of myocytes in culture.  
(Left: picture of electrical stimulator; Right: Modified cover of a 6-well dish for 
stimulation) 
 
Specifications of the Muscle Cell Stimulator on Mar 4
th
, 2008 
 
Voltage 
 
Voltage is constant and accurate in the 6-well plates.  When set at 9v the true output is 
8.5v. 
 
There is a positive train and negative train consisting of 5 repetitions each at a frequency 
of 5Hz. 
 
Current 
 
The current across a 6-well plate with 3mL and 2mL of media is 37mA and 20mA 
respectively. 
 
When 6 plates (3mL) are attached to the stimulator the current is 130mA. 
When 5 plates (3mL) are attached to the stimulator the current is 105mA. 
 
The current in a 10cm plate with 15mL is 7mA. 
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When there is more contact between the wires and the media there is more current, 
therefore if the wires are pushed down it makes a considerable difference than if they are 
up or just touching the media. 
 
Resistance 
 
The resistance across a 6-well plate with 3mL and 2mL of media is 12 KΩ and 350KΩ 
respectively (direction of measurement makes no difference, see below). 
 
The resistance in a 10cm plate with 15mL seems to be more confusing in one direction it 
is 1 6MΩ and the other direction it is 700KΩ    oth of these are not constant and seem to 
change with time in an opposite manner… Jim says it seems to act as a semiconductor … 
needs to be measured again. 
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Cytochrome C Oxidase Assay for Microplate Reader 
 
J. Biol. Chem. 189:665, 1951,  
Meth. Biochem. Anal. 2:427, 1955,  
Meth. Enzymol. 10:245, 1967. 
 
THEORY: 
Tissue extract containing cytochrome c oxidase is added to the test solution 
containing fully reduced cytochrome c. The rate of cytochrome c oxidation is measured 
over time as a reduction in absorbance at 550 nm. The reaction is carried out at 30
o
 C.  
 
REAGENTS: 
 
1. 20 mM KCN;  MW= 65.12, 13.02 mg/10 ml dH2O 
 
2. 100 mM K-Phosphate Buffer 
 
- make up 0.1 M KH2PO4;     MW= 136.09  
= 13.6 g/1000 ml 
 (pH approx. 5) 
 (rm. temp) 
- make up 0.1 M K2HPO4.3H2O;    MW= 174.18 
= 17.4 g/1000 ml 
 (pH approx. 8) 
 (rm. temp) 
- mix in equal proportions, pH to 7.0 
 
3. 10 mM K-Phosphate Buffer 
 
- dilute 0.1 M KPO4 Buffer prepared above 1:10 with ddH2O (eg. 10 ml buffer + 
90 ml ddH2O) 
 
4.  Extraction Buffer (100 mM Na-K-Phosphate, 2 mM EDTA; pH 7.2) 
 
- 500 ml 0.1 M Na2HPO4. 2H2O;  
 
   Combine 8.9 g sodium phosphate with 0.372 g EDTA up to 
500 ml. 
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- 200 ml 0.1 M KH2PO4;                               
 
Combine 2.7 g potassium phosphate with 0.149 g EDTA up 
to 200 ml. 
 
- combine both solutions and pH to 7.2      
                                                           
5. Test Solution (reduced cytochrome c, 2 mg/ml), for 10 ml (enough for 36 microplate 
wells); 
 
- weigh out 20 mg of horse heart cytochrome c (Sigma, C-2506) in a scintillation 
vial 
 
- add 1 ml of 10 mM KPO4 buffer and dissolve cytochrome c 
 
- make up a small volume of 10 mg/ml sodium dithionite-10 mM KPO4 stock 
solution (make fresh each experiment and use within twenty minutes) 
 
- add 40 μl of the dithionite stock solution to the test solution and observe red-
orange colour change 
 
- add 8 ml of ddH2O 
 
- add 1 ml of 100 mM KPO4 buffer. 
 
PROCEDURE: 
 
1:  Wash 10 cm plates 2x with chilled PBS. 
2: Add 500 µl of PBS per plate and scrape with a rubber policeman.  Combine 
supernatant from  2- 10cm plates and transfer to Eppendorf. 
3: Place whole cell lysate samples in liquid N2. Thaw in a 37°C water bath for 5 
min. Repeat freeze-thaw cycle. 
4: Place the Eppendorf tubes in the aluminium block on ice and Sonicate each tube 3 
x 3 seconds, cleaning the probe between samples. 
 
8.  Add 200 μl of Test Solution into 4-8 wells of 96-well microplate and incubate at 
30°C for 10 minutes to stabilize the temperature and absorbance. 
 
9. Open KC4 plate reader program (on Triton).  Select CONTROL icon, then PRE-
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HEATING tab, enter 30°C and select ON.  (Do not run assay until KC4 
temperature has reached 30°C.) 
 
10. Select WIZARD icon, then READING PARAMETERS icon. 
 
 Select Kinetic for Reading Type. 
 Select Absorbance for Reader and 550 nm for wavelength (drop-down 
menu). 
 Select Sweep for Read Mode. 
 Select 96 Well Plate (default) for Plate Type. 
 Enter first and last well to be read (eg. A1 and A4 if reading 4 samples 
simultaneously). 
 Select Yes and Pre-heating and enter 30 for Temperature Control. 
 For Shaking enter 0 for both intensity and duration (shaking is not 
necessary and it will delay the first reading).  
 Do not select either of the two options for Pre-reading. 
  lick on the KINETI … rectangular tile to open the Kinetic window  
 Enter run time (1 minute is recommended) and select MINIMUM for 
Interval time (under these conditions the minimum Interval time should be 
3 seconds). 
 Select Allow Well Zoom During Read to see data in real time (optional). 
 Under Scales, checkmarks should appear for both Auto check boxes.  Do 
not select Individual Well Auto Scaling. 
 Press OK to return to Reading Parameters window.  Press OK to return to 
Wizard window.  Press OK.  Do not save the protocol. 
 
11. Set the multipipette to 250 μl and secure 4-8 yellow tips on the white projections 
(make sure they are on tight and all at the same height). 
 
12. In a second, clean 96 well plate, pipette samples into 4-8 empty wells (start with 
A1).  Recommended volumes: 30 μl of 80-fold extract for Mixed Gastroc, 10 μl 
for Heart.  Adjust volumes according to oxidative capacity of the tissue.  (eg.  25 
μl for Red Gastrocnemius and 35 μl for White Gastrocnemius).  
 
13. Remove microplate with Test Solution in 4-8 wells from the incubator (as long as 
it has been incubating for 10 minutes).  Place this plate beside the plate with the 
sample extracts in it. 
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14. On KC4 program, select the READ icon and press the START READING icon, 
then press the REA  PLATE button   A box will appear that says, “Insert plate 
and start reading”    o not press OK yet, but move the mouse so that the cursor 
hovers over the OK button. 
 
15. Using the multipipette (set to 250 μl) carefully draw up the Test Solution.  Make 
sure the volume is equal in all the pipette tips, and that no significant air bubbles 
have entered any of the tips. 
 
16. Pipette the Test Solution into the wells with the sample extracts (the second 
plate).  As soon as all the Test Solution has been expelled from the tips (do not 
wait for the second push from the multipipette), place the plate onto the tray of the 
plate reader and with the other hand on the mouse, press the OK button.  (Speed at 
this point is paramount, as there is an unavoidable latency period between the 
time of pressing the OK button and the time of the first reading.)  
 
17. If desired, add 5 μl KCN to one of the wells to measure any absorbance changes 
in the presence of the CYTOX inhibitor. 
  
18. Once reading is complete, hold the CTRL key on the keyboard, and use the mouse 
to click once on each of the squares corresponding to a well that had sample in it.  
Once all the desired wells have been highlighted by a black square (up to a 
maximum of 8 wells), let go of the CTRL key and a large graph will appear with 
lines on it representing each sample.   
 
19. To obtain the rate of change of absorbance over different time periods, select 
Options and enter the amount of time for which you would like a rate of change of 
absorbance to be calculated.  The graph, along with one rate (at whichever time 
interval is selected) for each sample can be printed on a single sheet of paper, and 
the results can be saved. 
 
20. The delta absorbance will appear in units of mOD/min and the number given will 
be negative.  Convert this to OD/min by dividing by 1000 and omit the negative 
sign in the calculation.  (eg. if Mean V: -394.8 mOD/mn, then use 0.395 OD/min) 
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CALCULATION:   CYTOX activity (μmole/min/g tissue) 
        =  delta absorbance/min x total volume (ml) x 80 (dilution)   
           18.5 (μmol/ml extinction coeff.) x sample vol (ml) 
Example Calculation: 
 
30 μl of 80-fold sample extract 
250 μl of Test Solution 
Mean V: -284.2 mOD/mn 
 
COX activity =  (.284)(.280)(80)   
        (18.5)(.030) 
 
= 11.5 μmol/min/g tissue 
 
= 11.5 U/g tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue Heart 
Mixed 
Gastroc 
Weight (mg) 5 mg 7.5 mg 
Vol. for 20-fold 100 μl 150 μl 
Remove, put in 
new Eppendorf 
50 μl 75 μl 
Vol. needed for 
80-fold 
Add 150 μl    
of extract. 
buffer 
Add 225 μl    
of extract. 
buffer 
Final Volume of 
80-fold 
200 μl 300 μl 
Vol. of 80-fold 
per well 
10 μl 30 μl 
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Fluorescence Microscopy 
C2C12 myoblasts were plated on custom-made glass bottom 6-well dishes coated with 
0.1% gelatin.  Upon 80-90% confluency, C2C12 myoblasts were co-transfected with the 
mitoDSred and pbabe GFP-LC3 construct using Lipofectamine 2000 reagent (Life 
Technologies).  Transfection efficiency was estimated at 40%.  Following transfection, 
media was replaced with DM to induce differentiation.  DM was replenished daily and 
day 4 myotubes were subject to the same CCA protocol described earlier.  21 hours post 
the final bout of chronic contractile activity (CCA), live-cell fluorescence microscopy 
was performed to visualize mitochondria and LC3. Fluorescence was visualized using an 
inverted Nikon Eclipse TE2000-U fluorescent microscope equipped with 100x oil 
objective lens, with a custom designed chamber designed to maintain a constant 
temperature of 37
o
C with 5% CO2.  All images were taken at the same exposure and 
representative images reflect a minimum of 30 images per condition, as well as repeated 
experiments. 
-For BafA treated myotubes. Cells were exposed to four different treatments, vehicle 
control, veh CCA, 3 nM BafA control, 3 nM BafA +CCA.   
Materials 
-pBABE GFP-LC3(Addgene) which is localized to autophagosome membranes after 
processing. 
 
-pDsRed2-Mito (Clontech, CA, USA),  an expression vector that encodes a fusion of red 
fluorescence protein and the mitochondrial targeting sequence from COX subunit VIII. 
 
-Lipofectamine 2000 (Life Technologies, CA, USA) 
 
- Nikon Eclipse TE2000-U fluorescent microscope equipped with 100x oil objective lens 
 
-C2C12 cells (ATCC, Manassas, VA) 
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Mitochondrial Isolation from C2C12 Myotubes 
 
REFERENCES: Frezza et al., Nature Protocols 2007; 2(2):287-95. 
 
SOLUTIONS: 
Mitochondrial Isolation Buffer (MIB)  (*make fresh) 
1. 10 ml of 0.1 M Tris-MOPS (store at 0-4°C) 
0.1 M Tris   6.05 g / 500 ml 
pH to 7.4 using MOPS 
 
2. 1 ml  of 0.1 M EGTA/Tris (store at 0-4°C) 
0.1 M EGTA   19.05 g / 500 ml 
pH to 7.4 using Tris 
 
3. 20 ml of 1 M sucrose  (*make fresh) 
1 M sucrose   34.33 g / 100 ml 
ISOLATION PROCEDURE: 
 This final isolation procedure has been determined to be the optimal method for 
the isolation of intact mitochondria from the tissue culture of C2C12 myotubes through 
differential centrifugation.  The entire procedure is done at 4°C (everything to be kept on 
ice). 
 
1:  Set out materials ( get 2 buckets of ice and chill Teflon pestle and glass potter (15 
ml), centrifugation tubes, 15 ml conical tube, 200 ml of MIB and PBS on ice). 
2:  Remove the 10 cm plates from the incubator, and wash 2x with ice-cold PBS 
(keep plates on ice).  
3:  Add ~1.5 ml of MIB per plate, and quickly and gently scrape the plates with a 
rubber policeman, rotate the plate 45° and re-scrape to ensure all the cells have 
detached.  Transfer the scraped cells into chilled pre-labelled mitochondrial 
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isolation tube and keep on ice and cap when done.  If using for mitochondrial 
respiration use a minimum of 10 x 10 cm plates.     
 ---- Repeat this step for each sample ----  
4:   At a centrifuge setting of 600 g, with Beckman JA25.5 ROTOR, centrifuge the 
samples for 10 min.  Discard the supernatant and Resuspend the pellet in 3 ml of 
ice-cold MIB. 
5:    Transfer the suspension into a chilled 15 ml Potter-Elvehjem.  Homogenize the 
cells using the PTFE Tissue Grinders at 800 rpm for 35 strokes.  Set timer to 
ensure consistency between samples.   
6:      Transfer the supernatant to a fresh tube and centrifuge for 10 min at 600g, transfer 
only the supernatant gently through a falcon tube fitted with a 45 μm filter, being 
careful to avoid the pellet.   
7:   Collect the supernatant and (contains mitochondria and cytosol) and transfer to a 
clean pre-chilled mitochondrial isolation tube.  Quick spin at 600 g for 3 min to 
ensure that any remaining cellular debris is pelleted, now transfer only the 
supernatant to the last fresh tube. 
8: Centrifuge the supernatant at 9,000 x g for 10 min. at 4
°
C. 
9: Discard the supernatant and the resultant pellet is the mitochondria. 
10:  Gently Resuspend the pellet in 400 µl of MIB and transfer mitochondrial solution 
to a 1.5 ml Eppendorf. 
11:   Spin in a microcentrifuge at 9,000 x g for 10 min. at 4°C. 
12:  Discard the supernatant and re-suspend the mitochondria in 80-120 µl of MIB 
depending on mitochondrial yield.  Record the final volume and perform a 
Bradford assay to assess total µg of mitochondrial yield.  
13:  Use fresh mitochondria immediately for respiration and ROS analysis.  
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Mitochondrial Respiration 
(Muscle) Estabrook, R.W., Meth. Enzymol., 10: 41-47 (1967) 
 
THEORY: 
The rate of mitochondrial respiration is an important consideration in the 
biochemical analysis of mitochondria.  There are three phases of interest in analyzing the 
respiratory ability of mitochondria.  Mitochondria produce ATP in the presence of 
oxygen.  The respiratory ability of the freshly isolated mitochondrial fractions and the 
homogenates can be illustrated by measuring the rate of oxygen consumption using a 
Clark oxygen electrode in the presence of a) the substrate alone (e.g. glutamate for state 4 
or resting respiration); b) ADP, (state 3 or active respiration); and c) NADH
+
, which is 
used to measure the amount of damage that has occurred to the mitochondria, since the 
inner membrane is impermeable to NADH
+
. 
 
SOLUTIONS: 
VO2 Buffer for muscle mitochondria : 
  250 mM Sucrose (FW=342.30)  42.8  g/500 ml 
     50 mM KCl (FW=74.55)  1.86 g/500ml 
     25 mM Tris-HCl *  1.97 g/500ml             
10 M K2HPO4 (FW=174.18)   0.871 g/500ml 
 
*In place of 25mM Tris-HCl you can use 25 mM Tris (aka Tris 
(hydroxymethylamine).  This works out  to 1.5125 g/500ml (FW=121.4).  Using 
Tris in place of Tris-HCl means that you will have to add more HCl to get the pH 
down to 7.4. 
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Substrate for Muscle  
1. Glutamate  (MW= 147.13 g/mol) final conc. of 11.1 mM  
840 mM initial conc. (123.34)  mg/ml) 
 
 
2. ADP  (MW = 427.2 g/mol) - Final conc of 0.44 mM  
80 mM initial conc.  (34.1) mg/ml) 
  
3. NADH  (MW = 709.4 g/mol).  Final conc.: 2.8 mM   
0.5 M initial conc. ( 354.7 mg/ml) 
 
Mitochondrial Respiration Procedure 
 1:  Set water bath at 30
o
C - clean out chambers (Clark oxygen electrode; Yellow 
Springs Inst. Co., Yellow Springs, OH) and stir bars. 
2: Add 200 µl of VO2 Buffer to the chamber. 
3: Remove all bubbles in the chamber and allow it to reach equilibrium temperature 
(30
o
C). 
4: Put in 100 µl of isolated mitochondria from tissue culture and begin spinning. 
5: Allow a steady state oxygen consumption to be reached. 
6: Calibrate high to 100% and begin recording, allow sufficient time to calculate 
drift or basal respiration. 
7: Add 5 µl of Glutamate (State IV). 
8: Wait for slope to stabilize and add 5µl ADP (State III). 
9: Finally add 5 µl of NADH.  Prepare the next chamber while the respiration 
recordings are being made. 
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10: Clean out the chamber in the following manner: Remove the electrode and 
aspirate, remove the magnetic stir bar and aspirate, and finally, clean the electrode 
by rinsing with distilled water and pat dry. 
11: Put electrode in the next chamber (which should already have the buffer and 
sample in it).  
12:  Prepare the next chamber while measuring the respiration of the current chamber 
(ie. add 2 ml of VO2 Buffer and allow to equilibrate). 
13: Calculate the state 4, state 3 and NADH
+
 rates for each sample. Remember that 
the chart speed is 3 cm/sec and full scale is 100 %. (slope=rate=blocks/min) 
14: Calculate the rates of state 3 and state 4 respiration per mg of mitochondrial 
protein by dividing the state 3 and 4 rates by the amount of protein (mg) added to 
the VO2 Buffer.  
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Western Blot Procedure 
Part A: SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) – Bio-Rad Mini 
Protein System 
Reagents: 
 Acrylamide/Bis-Acrylamide, 30% Solution 37.5:1 (BioShop 10.502) 
o Store at 4°C 
 Under Tris Buffer 
o 1M Tris-HCl, pH 8.8 (60.5g/500mL) 
o Store at 4°C 
 Over Tris Buffer 
o 1M Tris-HCl, pH 6.8 (12.1g/100mL) 
o Bromophenol Blue (for colour) 
o Store at 4°C 
 Ammonium Persulfate (APS) 
o 10% (w/v) APS in ddH20 (1g/10mL) 
o Store at 4°C 
 Sodium Dodecyl Sulfate (SDS) 
o 10% (w/v) in ddH20 (1g/10mL) 
o Store at room temperature 
 TEMED (Sigma T-9281) 
 Electrophoresis Buffer, pH 8.3 (10L) 
o 25 mM Tris 30.34g, 192mM Glycine 144g, 0.1% SDS 10g 
o Volume to 10L with ddH20 
o Store at room temperature 
 2 x Lysis Buffer 
 tert-Amyl alcohol ReagentPlus, 99% (Sigma 152463) 
Procedure: 
1. Prepare Mini-Protean gel caster system: 
a. Assemble glass plates as shown below:  
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2. Prepare separating gels: 
 
Mini Protean 3 Bio-Rad System volumes 
Separating Gel 8 % 10 % 12 % 15 % 18 % 
Acrylamide 2.7 ml 3.3 ml 4.0 ml 5.0 ml 6.0 ml 
Water 4.1 ml 3.5 ml 2.8 mL 1.8 ml 0.8 ml 
Under Tris 3.0 ml 3.0 ml 3.0 ml 3.0 ml 3.0 ml 
SDS 100 μl 100 μl 100 μl 100 μl 100 μl 
APS 100 μl 100 μl 100 μl 100 μl 100 μl 
TEMED 20 μl 20 μl 20 μl 20 μl 20 μl 
 
a. Mix the contents of the separating gel without TEMED.  
b. Add TEMED. Briefly stir. Immediately, pour the contents between the 
short and spacing plates until the volume reaches 2 cm from the top 
edge of the short plate 
c. Coat the top surface of the gel solution with tert-Amyl alcohol to 
remove any bubbles. 
d. Allow 10 - 30 minutes for gel polymerization.  
e. Remove tert-Amyl alcohol by pouring it off, rinse briefly with ddH20 
and remove any remainder by tilting caster to the side and absorbing 
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fluid with a scrap piece of Whatman paper, being careful not to touch 
gel. 
3. Prepare stacking gel: 
a. For a single mini gel use the following volumes: 
 
Stacking Gel (3% 
Acrylamide) 1 Mini Gel 
Acrylamide 250 μL 
Water 1.875 mL 
Above Tris buffer 312 5 μL 
SDS 25 μL 
APS 25 μL 
TEMED 8 μL 
 
b. Mix the contents of the stacking gel without adding TEMED. Stir.  
c. Add TEMED. Stir and pour the stacking gel on top of the polymerized 
separating gel.  
d. Immediately, add the appropriate comb for desired number of wells 
and thickness of spacer plate. 
e. Allow 10 - 30 minutes for gel polymerization. 
f. Gels may be used immediately or stored in a wet sealed container at 
4ºC.  
4. Prepare samples: 
a. Warm block heater to 95ºC.  
b. Pipette the appropriate volume of each sample into a new Eppendorf. 
This volume is determined by the protein concentration assessed using 
the Bradford assay and the required amount of protein required for 
the detection of the desired protein. 
c. Add an equal amount of 2X Lysis Buffer supplemented with 5% B-
Mercaptoethanol  Add 5 μL of  ample  ye to each sample  
d. Briefly spin each sample to bring volume to the bottom of the 
eppendorf. 
e. Incubate each sample at 95ºC for 5 minutes in the heating block to 
denature the proteins.  
f. Briefly centrifuge again to return volume to the bottom of the 
Eppendorf. 
 
5. Assemble Mini-Protean electrophoresis rack: 
a. See images below: 
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b. If you are only running one gel a plastic rectangular pseudo plate must 
be clamped on the other side of the caster.  
c. Fill the middle chamber of the electrophoresis apparatus with 
Electrophoresis Buffer. Fill the outer chamber with Electrophoresis 
Buffer, until the level is approximately 2 cm above the bottom of the 
gels.  
d. Slowly remove the comb using both hands (one on each side) by 
pulling the comb straight upwards.  
e. Fix any wells that are deformed using a pipette tip.  
f. Clean out the wells using a pipette tip and Electrophoresis Buffer. 
g. Apply 10 μL of protein ladder to the first well   
h. Withdraw the entire volume of the sample using a gel-loading tip. 
Inject the solution slowly into the bottom of the well.  
 
6. Gel Electrophoresis: 
a. After all samples are loaded, immediately, place the lid on the gel 
chamber. 
b. Place the positive and negative leads into the power supply. 
c. Use a power supply to apply a constant voltage of 120V across the gel 
for 60 – 120 minutes, until sufficient separation has been achieved as 
indicated by the protein ladder. 
d.  Prepare for electrotransfer of proteins from the gel to nitrocellulose 
membrane.  
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Part B: Western Blotting and Immunodetection 
Reagents: 
 Transfer Buffer 
o 0.025M Tris-HCl pH 8.3  = 12.14g 
o 0.15M Glycine   = 45.05g 
o 20% Methanol  = 800mL 
o Make 4L with ddH20 
o Store at 4°C 
 Ponceau S stain 
o 0.1% (w/v) Ponceau S  
o 0.5% (v/v) Acetic Acid 
o Store at room temperature 
 Wash Buffer 
o Tris-HCl pH 7.5    12g 
o NaCl    58.5g 
o 0.1% Tween   10mL 
o Store at room temperature 
 Blocking Buffer 
o 5% (w/v) skim milk powder in Wash Buffer 
 Enhanced Chemiluminescence Fluid (ECL; Santa Cruz - SC-2048) 
 Film Developer and Fixer 
Procedure: 
1. Transfer Procedure 
a. Using a paper cutter and cut 6 pieces of Whatman paper per gel. Each 
piece should measure 8.5 cm x 6 cm. Wearing gloves cut an 8.5cm x 6 
cm piece of nitrocellulose membrane (GE Healthcare RPN303D). 
Soak Whatman paper and nitrocellulose membrane in Transfer Buffer 
until use. 
b. Remove electrophoresis plates from chamber and separate the plates. 
c. Remove stacking gel 
d. Assemble Whatman paper, nitrocellulose membrane and gel as shown 
below, ensuring that the gel and membrane are orientated so that the 
gel is closer to the black surface and the membrane closer to the white 
plastic clamp. 
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e. Close the cassette and place in the transfer chamber with the black side 
of the cassette facing the negative electrode (black side) of the 
chamber.  
f. Place an ice pack and magnetic stir bar in the chamber. 
g. Place the chamber in a Tupperware container. Place the container on 
top of a magnetic stir plate. Turn on the stir plate and ensure the 
magnetic stir bar is spinning. 
h. Fill the chamber completely with cold Transfer Buffer. Place lid on the 
chamber and connect the leads to a power supply.  
i. Turn on the power supply and apply a constant voltage of 120V for 1.5 
hours. This can vary depending on the size of the protein of interest. 
2. Removal of nitrocellulose membrane: 
a. Turn off the power supply and disconnect leads from the power 
supply. 
b. Remove the cassette from the chamber.  
c. While wearing gloves, carefully dispose of the Whatman paper and 
gel. 
d. Gently place the nitrocellulose membrane in a plastic dish and apply 
Ponceau S stain for 2 minutes.  
e. Drain off the remaining Ponceau S and save for reuse. 
f. Rinse the membrane with ddH2O to reduce the red background. Wrap 
membrane in saran wrap and scan. 
g. Cut the membrane while protein bands are still visible at the desired 
molecular weight. 
h. Rotate membrane at room temperature in Wash Buffer until remaining 
Ponceau S stain has been removed (~5 minutes). 
i. Incubate membrane for 1 hour with rotation in Blocking Buffer at 
room temperature.   
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3. Immunodetection 
a. Primary Antibody Incubation 
i. Wrap a flat piece of glass in parafilm. Place the glass in a 
Pyrex dish. Arrange balls of wet tissue around the dish and 
cover the entire dish with saran wrap. 
ii. Place the dish in a 4ºC fridge and level. 
iii. Place nitrocellulose membrane strips face up on the flat 
parafilm surface. 
iv. Dilute the primary antibody raised against the protein of 
interest in Blocking Buffer. Gently apply ~1-1.5 mL of diluted 
antibody overtop of the appropriate membrane strip. 
b. Secondary Antibody Incubation 
i. Wash the blots in Wash Buffer with gentle rotation for 5 
minutes 3X. 
ii. Incubate the blots as described in step 3.a with the following 
changes. Incubate the blots for 1 hour with a secondary 
antibody raised against the species and specific 
immunoglobulin molecule of the primary antibody. Incubate at 
room temperature. 
c. Following the incubation, wash the membrane 3X for 5 minutes with 
Wash Buffer. 
4. Enhanced Chemiluminescence Detection 
Note: Complete the following steps in a dark room sufficient for 
photographic film developing. 
a. Mix E L fluids “A” and “ ” in a 1:1 ratio in small beaker. 
b. Lightly dab off excess moisture by gently laying blot on a clean kim 
wipe and place blots face up onto plastic wrap surface, tape edges of 
plastic wrap to ensure smooth working surface.  Apply ECL to top 
surface of blots using a p1000 pipette. 
c. Following 2 minutes, remove blots and lightly dab on clean Kim wipes 
to remove excess ECL fluid. 
d. Place membrane strips on clean overhead transparency film and 
remove any bubbles. 
e. Turn off any lights. 
f. Place membrane strips face up in a film cassette and secure with tape.  
g. Prepare the film and apply film overtop of the membrane strips. Do 
not move the film once it has been placed on top of the membrane. 
h. Close the cassette and expose the film for the desired time.  
i. After a 30 sec exposure time, proceed to step j., use this initial 
exposure to gauge length required for subsequent exposures. 
j. Attach the film to a film hanger and immerse in the film developing 
solution for 8 seconds. 
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k. Hold the film up to a red light briefly, and re-submerse in developer if 
necessary. When bands become apparent, immediately submerge the 
film in water and then in the film fixing solution for a minimum of 15 
seconds. 
l. Following a minimum of 15 seconds in the fixing solution, the film 
can then be submerged in water and attached to butterfly binder clips 
to dry. They are no longer light sensitive. 
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RNA Isolation and qPCR 
Reagents: 
 TRIZol® Reagent 
 24:1 Chloroform:Isoamylalcohol 
o 24 parts Chlorofom 
o 1 part Isoamylalcohol 
 100% Isopropanol 
 75% Ethanol 
 DEPC ddH2O 
Procedure: 
5. Cell Culture: 
a. Grow cells in 10cm dish 
b. Pour off the medium. Wash each plate with 5mL of ice-cold Phosphate 
Buffered Saline (PBS), remove all of the PBS. 
c. Add 400 µl of PBS to plate and gently scrape with a rubber policeman. 
d. Transfer to Eppendorf. 
e. Centrifuge the cells at 14000 rpm for 3 min. Remove all supernate. 
Resuspend in 2 mL of PBS. 
f. Centrifuge the cells at for 3 min at 14000 rpm in a microcentrifuge. 
Discard the supernate with a Pasteur pipette. 
6. RNA Isolation 
a. Add 1ml TRIZOL.  Vortex thoroughly until pellet is completely 
disrupted. 
b. Add 200 μL of 24:1 chloroform:isoamlyalcohol  
c. Shake vigorously for 15 seconds and leave @ room temperature for 5 
minutes. 
d. Centrifuge at 14000 rpm for 15 minutes at 4oC. 
e. Transfer the upper phase carefully to a new Eppendorf tube.  Add 500 
μL of 100% isopropanol and briefly shake  
f. Incubate at room temperature for 30 minutes. 
g. Spin at 14000 rpm for 10 minutes at 4oC. 
h. Remove supernatant  Add 500 μL of 75% EtOH and wash the RNA 
pellet with gentle pipetting. 
i. Centrifuge at 14000 rpm for 1 minute at 4oC. 
j. Carefully, remove supernatant and air dry the RNA pellet. 
k. Resuspend the pellet in 50 μL of  EP  ddH2O. 
l. Heat RNA samples at 65oC for 10 minutes. 
7. Quantify RNA 
a. Use a spectrophotometer to measure the absorbance at 260 nm. 
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b. Freeze and store at -80oC. 
Part C: Reverse Transcriptase 
Reagents: 
 Oligo(dt) 20 
 10 mM dNTP 
 DEPC ddH2O 
 Master Mix (per sample) 
o 8 μL of 5x Buffer 
o 2 μL of 0 1 M  ithiothreitol ( TT) 
o 2 μL of RNAse Out 
 Superscript III 
Procedure: 
8.  ombine 2 μL of Oligo(dt) 20, 2 μL of 10 mM dNTP, and 4 μg of  ample 
RNA in a sterile 0.5 mL sterile Eppendorf   ring the volume to 26 μL with 
DEPC ddH2O. 
9. Heat the Eppendorf at 65ºC for 5 minutes, followed by 1 minute at 4ºC in a 
thermocycler. 
10. Make the Master Mix. 
11. After the Eppendorfs have been heated, add 12 μL of the Master Mix and 2 μL 
of Supercript III RT. 
12. Incubate the Eppendorf for 50 minutes at 55ºC, followed by 15 minutes at 
70ºC. 
13. Store samples at -20ºC. 
Part D: Quantitative Polymerase Chain Reaction (qPCR) Procedure  
Reagents: 
 DEPC ddtH2O 
 Master Mix (per sample and per gene of interest) 
 12 5 μL of Perfe Ta®  Y R® Green  uperMix with ROX™  
 2 5 μL of 20 μM  orward Primer 
 2 5 μL of 20 μM Reverse Primer 
 5 5 μL of  EP  ddH2O 
Procedure: 
14. Biochemical Assay 
a. Autoclave qPCR microtube strips and pipette tips. Sterilize pipettes 
with EtOH for use. 
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b. Dilute cDNA samples 1:20 with DEPC ddH2O. 
c.  
Create appropriate Master Mixes as determined during optimization. Always use 
a housekeeping gene to correct for difference in total cDNA amount. 
d. Add 2 μL of each diluted c NA sample in triplicate to microtube 
strips. 
e. Add 23 μL of Master Mix to all wells  
f. Close wells and place in Applied Biosystems StepOne Plus qPCR 
machine. 
g.  et the  tepOne Plus application for a reaction volume of 25 μL, 
SYBR® Green Technology, Normal (~2.5 hour) Reaction Speed, and 
Include a Melt Curve Analysis. 
15.  ∆∆Ct Analysis 
a. After the run is complete. Confirm that the automatically determined 
thresholds are in the exponential amplification phase for each gene of 
interest. Export all data to an Excel spread sheet. 
b. Obtain the cycle number where the sample’s amplification plot crosses 
the defined threshold (i.e. the Ct value). 
c. Average the two closest Ct values. 
d. To determine the ∆ t take the difference between the  t value of the 
gene of interest and the Ct value of your housekeeping gene. Raise this 
to the power of two (i.e. 2
∆ t
) and use this to compare differences in 
gene expression. 
e. To determine find the fold change in the gene expression from your 
control samples take the ∆ t of each sample and subtract the ∆ t of 
the control sample  Use these values (∆∆ t) to generate a graph of 
gene expression relative to your control condition 
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ROS Production from Isolated Mitochondria 
 
Background: Mitochondria are the primary source of reactive oxygen species (ROS) to 
the cell.  It is estimated that about 2% of total cellular oxygen is converted to ROS by the 
inappropriate reduction of molecular oxygen by intermediate members of the electron 
transport chain (ETC).  ROS are damaging molecules that are capable of compromising 
the integrity of macromolecules within the mitochondria and may lead to overall 
organelle dysfunction.  In particular, mtDNA may be prone to attack by ROS because 1) 
mtDNA is located in close proximity to the ETC, 2) mtDNA lacks the protective sheath 
of histones compared to nuclear DNA and, 3) mitochondria have an insufficient repair 
system for mtDNA mutations.   ROS can exist in a variety of molecular permutations 
such as superoxide  (O2
-
), hydroxyl radical (OH
-
) and hydrogen peroxide (H2O2).    
DCF (2,7,-dichloro-fluorescein; Fig.1) is a reagent that is non-fluorescent until the 
acetate groups are removed by intracellular esterases and oxidation occurs within the 
mitochondria (Fig.1).  DCF is oxidized by all of the different forms of ROS and this can 
be detected by monitoring the increase in fluorescence with a fluorometric plate reader.  
The appropriate plate reader filter settings for fluorescein are the following: Excitation 
485/20 and Emission 528/20 (Fig.2).  
         
  Fig.1-DCF molecule and oxidation of DCF resulting in fluorescence 
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Fig.2-Absorption and Emission Spectra of oxidized dye               
KC4 Software Settings: The Settings icon in the upper left corner allows the alteration of 
various parameters.  Once clicked, another window appears, click on the Wizard Icon.  In 
this window there will be a variety of components that can be altered.  The following are 
the parameters that need to be changed in order to utilize the DCF and measure time-
dependent ROS production from isolated mitochondria: 
 
1) Top Middle Panel- Absorbance, Fluorescence, Luminescence- choose Fluorescence 
2) Top Left Panel- End Point, Kinetic, Spectrum- choose Kinetic 
3) Top Middle Panel- Click on larger box labeled Kinetic to set parameters- Run Time 
1:20:00, Interval 5:00 (takes a measure every 5 minutes), click on box labeled Allow 
Well Zoom during Read, and also click on box labeled Individual Well Auto Scaling- 
The Well Zoom and Auto scaling allows for monitoring each individual well during the 
experiment and scales it appropriately. 
4) Middle Panel-Filter Set- Choose #1, then set the excitation to 485/20, and emission to 
528/20 as described above.  The optics position should be set to the TOP (i.e. readings 
are taken from the top of the well) and the sensitivity is set at 50 (depending upon the 
amount and/or nature of the sample).  
5) Plate-Type-choose 96-well plate, choose which wells are to be read i.e. A1-C12. 
6) Shaking-Intensity set at 1, Duration set at 15s and then click the box that is labeled 
before every reading (it shakes the samples for 15 s before every reading). 
  
139 
 
7) Temperature Control- Click on the box indicating YES , also click on box labeled pre-
heating, and put 37°C into the temperature box. 
 
DCF Reagent and VO2 Buffer 
 
DCF (2,7,-dichlorodihydrofluorescein diacetate) reagent MW=487.29 (Molecular Probes 
D-399/ 100mg) 
 
1°STOCK- Make up 50mM Stock Solution in EtOH- 24 mg/ml- only make about 500µl 
i.e. 14 mg per 500µl EtOH. Wrap stock solution in aluminum foil and limit exposure to 
light since DCF is light-sensitive. 
 
Working Stock Solution-2° STOCK- Dilute 50mM by 100-fold by taking 10μl and 
adding 990 μl of EtOH to attain a 500uM DCF Stock Solution.  This will be the DCF 
concentration used to add to the reaction mixture. 
 
VO2 Buffer- refer to mitochondrial respiration protocol 
 
Procedure 
 
1. Mitochondria are isolated as described in the mitochondrial isolation protocol.  
Alternatively, frozen mitochondrial extracts can also be used.  
 
2. Determine the volume necessary for 50µg of mitochondria.  Typical volumes should 
range between 5-40µl depending upon concentration of mitochondrial extracts. 
 
3. Final concentration of DCF is 50uM.  The total volume of the reaction mixture is 
250µl.  Thus, 25µl of DCF is used in the reaction mixture since this represents a 10-
fold dilution.  Set up table (as shown below) and determine the amount of VO2 buffer 
necessary to make each of the reaction mixtures equal to 250 µl.  (Remember to 
include a control with only VO2 buffer and DCF reagent as in Well #1 shown below)           
  SS 
       Control 
Mar.23 Mar.25 Mar.29 
  Well #1 Well #2 Well #3 Well #4 
µg mito 0 50 50 50 
µl mito 0.00 11.77 9.80 17.24 
VO2 Buff 225.00 213.23 215.20 207.76 
DCF (50uM) 25 25 25 25 
Total Volume 250 250 250 250 
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4. Once table is complete and volumes for all samples have been determined, place the 
frozen (already thawed) or fresh mitochondria, VO2 buffer and DCF (500uM) into a 
37°C circulating water bath for 5-10 min. 
 
5. Pipette the volume of VO2 buffer required for each of the samples followed by the 
mitochondrial samples into the appropriate wells of a 96-well plate.  In addition, 
include a well (usually in the corner well) with only 250 μl of VO2 buffer to monitor 
temperature (see below). Place the 96-well plate with the VO2 buffer and mitochondria 
into a 37°C incubator.  Using the YSI temperature probe, place the recording electrode 
into the well with buffer only and monitor the temperature until 37°C is reached.  
During this time, be sure that the KC4 software is set up and that the Biotek plate 
reader is pre-heating to 37°C. 
 
6. Once mitochondria and buffer have reached temperature (37°C), take the DCF out of 
the circulating water bath (37°C) and quickly add the DCF to each of the reaction 
mixtures.   Following addition of DCF, promptly place the plate into the Biotek plate 
reader for fluorescence measurement and start the KC4 program by pressing READ 
plate on the upper left portion of the computer screen.  Kinetic program will operate 
for 1 h and 20 min.   
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